Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L15	55957	antisense or triplex or ribozyme or RNAi or siRNA or "RNA interfer?" or "short interfer? RNA"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 10:58
L16	186	"human x-linked inhibitor of apoptosis" or hiap-1 or xiap or "x-linked iap" or "miha protein"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 10:59
L17	102723	cancer? or tumor? or carcinoma? or tumour?	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:00
L18	43	"follicular atresia?" or "atresia? follicular"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:00
L19	8642	"inflammatory disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L20	124	L15 AND L16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:01
L21	96	L20 AND L17	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:02
L22	1	L20 AND L18	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:02
L23	5	L20 AND L19	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:03
L24	812	"inflamm? disease" or "inflamm?" or "inflamm? disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L25	23	"inflammat? disease" or "inflammat?" or "inflammat? disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L26	111793	inflammatory	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04

L27	66	L20 AND L26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:05

```
Set     Items   Description
S1       4667   XIAP OR HIAP OR HILP OR MIHA
S2     213803   ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
              INTERFER? RNA)
S3    7369699   CANCER OR TUMOR OR CARCINOMA
S4       1106   FOLLICULAR ATRESIA?
S5    1627772   INFLAMMAT?
S6        287   S1 AND S2
S7         89   RD S6 (unique items)
S8         61   S7 AND S3
S9         61   RD S8 (unique items)
S10         0   S7 AND S4
S11         3   S7 AND S5
? t s8/free/all
>>>"FREE" is not a valid format name in file(s): 399
```

8/6/1 (Item 1 from file: 5)
0015002823 BIOSIS NO.: 200400373612
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
2004

8/6/2 (Item 2 from file: 5)
0014973429 BIOSIS NO.: 200400344218
Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome-linked inhibitor of apoptosis protein in resistant human glioma cells
2004

8/6/3 (Item 3 from file: 5)
0014959816 BIOSIS NO.: 200400330602
X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer **cells**
2004

8/6/4 (Item 4 from file: 5)
0014945078 BIOSIS NO.: 200400315835
Cyr61 expression confers resistance to apoptosis in breast cancer **MCF-7 cells by a mechanism of NF-kappaB-dependent** XIAP **up-regulation**
2004

8/6/5 (Item 5 from file: 5)
0014905560 BIOSIS NO.: 200400276317
Specific downregulation of bcl-2 and xIAP **by** RNAi **enhances the effects of chemotherapeutic agents in MCF-7 human breast** cancer **cells**
2004

8/6/6 (Item 6 from file: 5)
0014846985 BIOSIS NO.: 200400217040
Regulation and targeting of antiapoptotic XIAP **in acute myeloid leukemia.**
2003

8/6/7 (Item 7 from file: 5)
0014818352 BIOSIS NO.: 200400186038
Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).
2004

8/6/8 (Item 8 from file: 5)
0014795073 BIOSIS NO.: 200400162414
Mechanisms of apoptosis induction by a novel ring-substituted diindolylmethane (1,1-bis (3'-(5-methoxy indolyl))-1-(p-t-butylphenyl) methane) (BMIPTM) in leukemic cells.
2003

8/6/9 (Item 9 from file: 5)
0014780228 BIOSIS NO.: 200400146889
The triterpenoid CDDO-imidazolide induces apoptosis of CLL B-cells, through a Bcl-2-independent mechanism and synergizes with fludarabine.
2003

8/6/10 (Item 10 from file: 5)
0014730212 BIOSIS NO.: 200400100969
Induction of cIAP-2 in human colon cancer **cells through PKCdelta/NF-kappaB.**
2003

8/6/11 (Item 11 from file: 5)
0014727376 BIOSIS NO.: 200400098133
RNAi **mediated downregulation of bcl-2 and xlAP may have therapeutical potential in human breast adenocarcinoma.**
2003

8/6/12 (Item 12 from file: 5)
0014581909 BIOSIS NO.: 200300538099
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and **NF-kappaB-dependent process.**
2003

8/6/13 (Item 13 from file: 5)
0014387492 BIOSIS NO.: 200300346211
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1.
2003

8/6/14 (Item 14 from file: 5)
0014380229 BIOSIS NO.: 200300336972
Bcl-2 Antisense **Treatment for Waldenstrom's** Macroglobulinemia.
2002

8/6/15 (Item 15 from file: 5)
0014080092 BIOSIS NO.: 200300038811
Role of XIAP **in the malignant phenotype of transitional cell** cancer **(TCC) and therapeutic activity of** xiap antisense **oligonucleotides against multidrug-resistant TCC in vitro.**
2003

8/6/16 (Item 16 from file: 5)
0013916537 BIOSIS NO.: 200200510048
A novel tri-specific antisense **oligonucleotide (AO) to the Inhibitors of Apoptosis Proteins (IAPs) enhances** apoptosis in PC3 prostate cancer **cells**
2002

8/6/17 (Item 17 from file: 5)
0013815621 BIOSIS NO.: 200200409132
Antisense **oligonucleotides targeting** XIAP **induce apoptosis and enhance therapeutic activity against human lung** cancer **cells when combined with anticancer drug in vitro and in vivo**
2002

8/6/18 (Item 18 from file: 5)
0013365117 BIOSIS NO.: 200100536956
Survivin inhibition induces human neural tumor **cell death through caspase-**independent and -dependent pathways
2001

8/6/19 (Item 19 from file: 5)
0013254012 BIOSIS NO.: 200100425851
Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells
2001

8/6/20 (Item 20 from file: 5)
0013249225 BIOSIS NO.: 200100421064
XIAP : **Apoptotic brake and promising therapeutic target**
2001

8/6/21 (Item 21 from file: 5)
0013237922 BIOSIS NO.: 200100409761
Gene therapy that inhibits nuclear translocation of nuclear factor kappaB **results in** tumor **necrosis factor alpha-induced apoptosis of human synovial fibroblasts**
2000

8/6/22 (Item 22 from file: 5)
0012930183 BIOSIS NO.: 200100102022
Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor **necrosis factor**

alpha-induced apoptosis
2001

8/6/23 (Item 23 from file: 5)
0012919888 BIOSIS NO.: 200100091727
Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins
2001

8/6/24 (Item 24 from file: 5)
0012897193 BIOSIS NO.: 200100069032
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression
2000

8/6/25 (Item 25 from file: 5)
0012810857 BIOSIS NO.: 200000529170
Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells
2000

8/6/26 (Item 26 from file: 5)
0012731647 BIOSIS NO.: 200000449960
Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death
2000

8/6/27 (Item 27 from file: 5)
0012655181 BIOSIS NO.: 200000373494
Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression
2000

8/6/28 (Item 28 from file: 5)
0012599835 BIOSIS NO.: 200000318148
Apoptosis and chemoresistance in human ovarian cancer : Is Xiap a determinant?
2000

8/6/29 (Item 1 from file: 440)
19534580 Document Delivery Available: 000224692500008 References: 58
TITLE: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865HE

8/6/30 (Item 2 from file: 440)

19532380 Document Delivery Available: 000224732800007 References: 54
TITLE: Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP **downregulation** (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865VR

8/6/31 (Item 3 from file: 440)
19532375 Document Delivery Available: 000224732800002 References: 158
TITLE: Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer ? (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865VR

8/6/32 (Item 4 from file: 440)
19524265 Document Delivery Available: 000224756000008 References: 46
TITLE: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1 (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 866EG

8/6/33 (Item 5 from file: 440)
19519481 Document Delivery Available: 000224701500004 References: 72
TITLE: The inhibitor of apoptosis protein family and its antagonists in acute leukemias (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865KL

8/6/34 (Item 6 from file: 440)
19358336 Document Delivery Available: 000224076900013 References: 33
TITLE: Down-regulation of procaspase-8 expression by focal adhesion kinase protects HL-60 cells from TRAIL-induced apoptosis (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 856WS

8/6/35 (Item 7 from file: 440)
19289502 Document Delivery Available: 000223885100005 References: 28
TITLE: XIAP **and survivin as therapeutic targets for radiation sensitization in preclinical models of lung** cancer (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 854EX

8/6/36 (Item 8 from file: 440)
16717231 Document Delivery Available: 000184578900004 References: 39
TITLE: Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells (ABSTRACT AVAILABLE)
2003
GENUINE ARTICLE#: 708QF

8/6/37 (Item 9 from file: 440)
16540070 Document Delivery Available: 000184108700056 References: 40
TITLE: Antisense **oligonucleotides targeting** XIAP **induce apoptosis and enhance chemotherapeutic activity against human lung** cancer **cells in vitro and in vivo** (ABSTRACT AVAILABLE)
2003
GENUINE ARTICLE#: 700JK

8/6/38 (Item 10 from file: 440)
14870510 Document Delivery Available: 000178519100042 References: 44
TITLE: The triterpenoid CDDO induces apoptosis in refractory CLL B cells (ABSTRACT AVAILABLE)
2002
GENUINE ARTICLE#: 602RW

8/6/39 (Item 11 from file: 440)
12401967 References: 47
TITLE: Livin, a novel inhibitor of apoptosis protein family member (ABSTRACT AVAILABLE)
2001
GENUINE ARTICLE#: 398YW

8/6/40 (Item 1 from file: 155)

16255410 PMID: 14990073
[Expression and significance of apoptosis protein inhibitor survivin and XIAP , in patients with myelodysplastic syndromes and in the cell line MUTZ-1]
Jan 2004
Tags: Human; Support, Non-U.S. Gov't
Descriptors: *Apoptosis; *Harringtonines--therapeutic use--TU; *Microtubule-Associated Proteins--genetics--GE; *Myelodysplastic Syndromes --pathology--PA; *Proteins--genetics--GE; Apoptosis--drug effects--DE; Cell Cycle--drug effects--DE; Cell Division--drug effects--DE; Microtubule-Associated Proteins--physiology--PH; Myelodysplastic Syndromes --drug therapy--DT; Oligonucleotides, **Antisense** --pharmacology--PD; Proteins--physiology--PH; RNA, Messenger--analysis--AN
CAS Registry No.: 0 (Harringtonines); 0 (IAP-like protein, vertebrate); 0 (Microtubule-Associated Proteins); 0 (Oligonucleotides, Antisense); 0 (Proteins); 0 (RNA, Messenger); 0 (survivin); 26833-87-4 (homoharringtonine)

8/6/41 (Item 2 from file: 155)

14387430 PMID: 10381630
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.
Apr 1999
Tags: Human; Support, Non-U.S. Gov't
Descriptors: *Apoptosis--genetics--GE; *Brain Neoplasms; *Gene Expression Regulation, Neoplastic; *Glioma; Adenoviridae--genetics--GE; Antigens, CD95 --genetics--GE; **Antisense** Elements (Genetics); Caspases--metabolism--ME;

Gene Transfer Techniques; Neoplasm Proteins--genetics--GE; Proteins --genetics--GE; **Tumor** Cells, Cultured--enzymology--EN; **Tumor** Cells, Cultured--pathology--PA; **Tumor** Cells, Cultured--physiology--PH
CAS Registry No.: 0 (Antigens, CD95); 0 (Antisense Elements (Genetics)); 0 (IAP-like protein, vertebrate); 0 (Neoplasm Proteins); 0 (Proteins)
Enzyme No.: EC 3.4.22.- (Caspases)

8/6/42 (Item 3 from file: 155)
DIALOG(R)File 155:(c) format only 2004 The Dialog Corp. All rts. reserv.

12432968 PMID: 12839953
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Jul 1 2003
Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Descriptors: *Apoptosis--drug effects--DE; *Benzamides--pharmacology--PD; *Cell Differentiation--drug effects--DE; *Cyclins--metabolism--ME; *Histone Deacetylases--antagonists and inhibitors--AI; *Pyridines--pharmacology--PD; *Reactive Oxygen Species--metabolism--ME; Cell Cycle--drug effects--DE; Cell Division--drug effects--DE; HL-60 Cells; Intracellular Membranes--drug effects--DE; Intracellular Membranes--physiology--PH; K562 Cells; Leukemia ; Membrane Potentials--drug effects--DE; Mitochondria--drug effects--DE; Mitochondria--physiology--PH; **Tumor** Cells, Cultured; U937 Cells
CAS Registry No.: 0 (Benzamides); 0 (Cip1 protein); 0 (Cyclins); 0 (N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide); 0 (Pyridines); 0 (Reactive Oxygen Species)
Enzyme No.: EC 3.5.1.- (Histone Deacetylases)

8/6/55 (Item 1 from file: 73)
12163838 EMBASE No: 2003265557
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21SUPCIP1/WAF1
01 JUL 2003

8/6/56 (Item 2 from file: 73)
11968278 EMBASE No: 2003076858
Resistance of human ovarian cancer **cells to** tumor **necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein**
01 FEB 2003

8/6/57 (Item 3 from file: 73)
11942842 EMBASE No: 2003053287
Regulation of Apo2L/ tumor **necrosis factor-related apoptosis**-inducing **ligand-induced apoptosis in thyroid** carcinoma **cells**
2002

8/6/58 (Item 4 from file: 73)
11088683 EMBASE No: 2001106169

Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor **necrosis factor alpha-induced apoptosis**
2001

8/6/59 (Item 1 from file: 144)
DIALOG(R)File 144:(c) 2004 INIST/CNRS. All rts. reserv.

16306294 PASCAL No.: 03-0470411
Antisense **oligonucleotides targeting** XIAP **induce apoptosis and enhance chemotherapeutic activity against human lung** cancer **cells in vitro and in vivo**
2003

English Descriptors: Human; In vitro; Established cell line; Malignant **tumor** ; Bronchopulmonary; **Tumor** cell; Biological activity; Animal; Mouse; In vivo; Treatment; Antineoplastic agent; Chemotherapy; Drug combination; **Antisense** oligonucleotide; Potentiation; Apoptosis; Cell death; Apoptosis inhibitory protein
Broad Descriptors: Rodentia; Mammalia; Vertebrata; Respiratory disease; Lung disease; Bronchus disease; Rodentia; Mammalia; Vertebrata; Appareil respiratoire pathologie; Poumon pathologie; Bronche pathologie; Rodentia; Mammalia; Vertebrata; Aparato respiratorio patologia; Pulmon patologia; Bronquio patologia

French Descriptors: Homme; In vitro; Lignee cellulaire etablie; Tumeur maligne; Bronchopulmonaire; Cellule tumorale; Activite biologique; Animal ; Souris; In vivo; Traitement; Anticancereux; Chimiotherapie; Association medicamenteuse; Oligonucleotide antisens; Potentialisation; Apoptose; Mort cellulaire; Gene **XIAP** ; Proteine inhibition apoptose

Classification Codes: 002B02R02

8/6/60 (Item 2 from file: 144)
DIALOG(R)File 144:(c) 2004 INIST/CNRS. All rts. reserv.

15534948 PASCAL No.: 02-0233325
Survivin inhibition induces human neural tumor **cell death through caspase-independent and -dependent pathways**
2001

English Descriptors: Apoptosis; **Tumor** cell; Cell death; Cysteine endopeptidases; Caspase; Human
Broad Descriptors: Peptidases; Hydrolases; Enzyme; Peptidases; Hydrolases; Enzyme; Peptidases; Hydrolases; Enzima

French Descriptors: Apoptose; Cellule tumorale; Mort cellulaire; Cysteine endopeptidases; Caspase; Homme; Survivine

Classification Codes: 002B04G01

8/6/61 (Item 3 from file: 144)
DIALOG(R)File 144:(c) 2004 INIST/CNRS. All rts. reserv.

14624714 PASCAL No.: 00-0295143

Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor necrosis factor alpha -induced apoptosis of human synovial fibroblasts

2000

English Descriptors: Rheumatoid arthritis; Treatment; Chemotherapy; Gene therapy; Mechanism of action; Inhibition; Translocation; Apoptosis; Cell death; **Tumor** necrosis factor alpha ; Fibroblast; Synovial membrane; In vitro; Human; Tissue culture; Chronic; Transcription factor NF kappa B

Broad Descriptors: Diseases of the osteoarticular system; Inflammatory joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme osteoarticulaire pathologie; Rhumatisme inflammatoire; Immunopathologie; Maladie autoimmune; Cytokine; Sistema osteoarticular patologia; Reumatismo inflamatorio; Inmunopatologia; Enfermedad autoinmune; Citoquina

French Descriptors: Polyarthrite rhumatoide; Traitement; Chimiotherapie; Therapie genique; Mecanisme action; Inhibition; Translocation; Apoptose; Mort cellulaire; Facteur necrose tumorale alpha ; Fibroblaste; Synoviale ; In vitro; Homme; Culture tissu; Chronique; Facteur transcription NF kappa B

Classification Codes: 002B15D

?

t s11/medium, k/all
>>>KWIC option is not available in file(s): 399

11/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013914248 BIOSIS NO.: 200200507759
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
AUTHOR: Bureau Fabrice (Reprint); Seumois Gregory; Jaspar Fabrice; Vanderplasschen Alain; Detry Bruno; Pastoret Paul-Pierre; Louis Renaud; Lekeux Pierre
AUTHOR ADDRESS: Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, Bat. B42, B-4000, Liege, Belgium** Belgium
JOURNAL: Journal of Allergy and Clinical Immunology 110 (3): p443-449 September, 2002 2002
MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...**survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation
...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-xL, or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .
DESCRIPTORS:
DISEASES: allergic **inflammation** --
CHEMICALS & BIOCHEMICALS: ...X-inhibitor of apoptosis protein { **XIAP** };

11/K/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141307497 CA: 141(19)307497m PATENT
Use of caspase inhibitors as antiviral agents, and test system for their discovery
INVENTOR(AUTHOR): Ludwig, Stefan; Planz, Oliver; Sedlacek, Hans-Harald; Pleschka, Stephan
LOCATION: Germany,

ASSIGNEE: Medinnova Gesellschaft fur Medizinische Innovationen aus Akademischer Forschung m.b.H.
PATENT: PCT International ; WO 200485682 A2 DATE: 20041007
APPLICATION: WO 2004DE646 (20040324) *DE 10313636 (20030326)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: C12Q-001/70A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/K/3 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

14624714 PASCAL No.: 00-0295143
Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor necrosis factor alpha -induced apoptosis of human synovial fibroblasts
ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU; CURIEL D T; MOUNTZ J D
University of Alabama at Birmingham, United States; Gene Therapy Program, Birmingham, Alabama, United States; University of Alabama at Birmingham, Birmingham, Alabama, United States; Veterans Administration Medical Center, Birmingham, Alabama, United States
Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
Language: English

... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence of TNFa. **XIAP** is an inhibitor of apoptosis which was up-regulated by TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific inhibitor of apoptosis in RA synovial cell lines. This and...
Broad Descriptors: Diseases of the osteoarticular system; **Inflammatory** joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme osteoarticulaire pathologie; Rhumatisme **inflammatoire** ; Immunopathologie ; Maladie autoimmune; Cytokine; Sistema osteoarticular patologia; Reumatismo inflamatorio; Inmunopatologia; Enfermedad autoinmune; Citoquina
?

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:25:47 ; Search time 0.001 Seconds
(without alignments)
40.400 Million cell updates/sec

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtccacctttttc 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 99 seqs, 1010 residues

Total number of hits satisfying chosen parameters: 198

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 99 summaries

Database : fetchrng8.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	20	100.0	20	1	AAA64908	Antisense oligonuc
	2	11.4	57.0	13	1	ABF25765	Oligonucleotide SE
c	3	11.4	57.0	13	1	ABF25764	Oligonucleotide SE
c	4	11	55.0	13	1	ABF81742	Oligonucleotide SE
	5	11	55.0	13	1	ABF81743	Oligonucleotide SE
c	6	10.4	52.0	13	1	ABH12912	Oligonucleotide SE
	7	10.4	52.0	13	1	ABH12913	Oligonucleotide SE
c	8	10	50.0	10	1	AAZ84451	Metastatic breast
c	9	10	50.0	10	1	ABQ72345	Human CYP2D6 gene
c	10	10	50.0	11	1	ABV71425	Human skin EST 921
c	11	10	50.0	11	1	ABV64836	Human skin EST 262
c	12	10	50.0	11	1	ABV64004	Human skin EST 179
c	13	10	50.0	12	1	ABI11479	Oligonucleotide pr
c	14	9.4	47.0	11	1	ADQ35262	Human hair-bearing
c	15	9	45.0	10	1	AAZ82410	Metastatic breast
c	16	9	45.0	10	1	AAZ83740	Metastatic breast
c	17	9	45.0	10	1	AAF34752	Yeast NORF gene SA
	18	9	45.0	10	1	AAF34921	Yeast NORF gene SA
c	19	8.4	42.0	10	1	AAQ96595	HIV-1 NL4-3 nef ge
c	20	8.4	42.0	10	1	AAQ96682	HIV-1 NL4-3 nef ge
c	21	8.4	42.0	10	1	AAX60279	M113 primer used t
	22	8.4	42.0	10	1	AAZ82548	Metastatic breast
	23	8.4	42.0	10	1	AAZ84690	Metastatic breast
c	24	8.4	42.0	10	1	AAZ84672	Metastatic breast
c	25	8.4	42.0	10	1	AAZ81424	Metastatic breast
	26	8.4	42.0	10	1	AAZ81367	Metastatic breast
c	27	8.4	42.0	10	1	AAZ84746	Metastatic breast
c	28	8.4	42.0	10	1	AAZ80933	Metastatic breast
	29	8.4	42.0	10	1	AAZ84569	Metastatic breast
	30	8.4	42.0	10	1	ABA81664	Human phospholipid
	31	8.4	42.0	10	1	ABA81653	Human phospholipid
	32	8.4	42.0	10	1	AAF42786	Yeast NORF gene SA
c	33	8.4	42.0	10	1	AAF41677	Yeast NORF gene SA
	34	8.4	42.0	10	1	ABL88346	Human CHRNE gene p
	35	8.4	42.0	10	1	ABK85694	Human SCYB6 gene p
c	36	8.4	42.0	10	1	ABV84283	Human alpha-1-anti
c	37	8.4	42.0	10	1	ABV84516	Human multiple HCC
c	38	8.4	42.0	10	1	ABK23690	Transcript tag DNA
c	39	8.4	42.0	10	1	ABL91889	Human LIPG gene pr
c	40	8.4	42.0	10	1	AAL40865	Zinc finger protei
	41	8.4	42.0	10	1	AAS94665	Human PLTP gene al
	42	8.4	42.0	10	1	AAS94676	Human PLTP gene al
c	43	8.4	42.0	10	1	ABN85904	Gamma tocopherol m
	44	8.4	42.0	10	1	ADG98610	Human CETP gene al
c	45	8.4	42.0	10	1	ACF57642	Human ALDOB gene a
c	46	8.4	42.0	10	1	ADJ78755	Arabidopsis gamma-
	47	8.4	42.0	10	1	ADI13651	Extracellular tumo
c	48	8.4	42.0	10	1	ADK12872	Human glioma endot
c	49	8.4	42.0	10	1	ADN00986	Gamma-tocopherol m
c	50	8	40.0	8	1	AAT09494	5'-primer used for
	51	8	40.0	8	1	AAT09575	3'-primer used for
	52	8	40.0	8	1	AAA80917	A. thaliana primer
c	53	8	40.0	8	1	AAA81227	A. thaliana primer
	54	8	40.0	8	1	AAA80895	A. thaliana primer
c	55	8	40.0	8	1	ADC45730	Nucleic acid-synth
	56	8	40.0	8	1	ADC45731	Nucleic acid-synth
c	57	8	40.0	10	1	AAV11229	Seq ID #45 from WO
	58	8	40.0	10	1	AAZ08340	Nilaparvata lugens
	59	8	40.0	10	1	AAZ08337	Nilaparvata lugens
	60	8	40.0	10	1	AAZ79431	Human dendritic ce
c	61	8	40.0	10	1	AAZ79551	Human dendritic ce
	62	8	40.0	10	1	AAZ85883	Metastatic breast
c	63	8	40.0	10	1	AAZ81064	Metastatic breast
c	64	8	40.0	10	1	AAZ83375	Metastatic breast
c	65	8	40.0	10	1	AAZ83135	Metastatic breast
c	66	8	40.0	10	1	AAZ83682	Metastatic breast
c	67	8	40.0	10	1	AAA56174	Human monocyte gen
c	68	8	40.0	10	1	AAH20011	Mouse Treg immunor
c	69	8	40.0	10	1	AAH63882	Human ubiquitously
c	70	8	40.0	10	1	AAH63884	Human ubiquitously
c	71	8	40.0	10	1	AAH64642	Human colon cancer
c	72	8	40.0	10	1	AAH64130	Human ubiquitously
c	73	8	40.0	10	1	AAH64694	Human highly expre
c	74	8	40.0	10	1	AAH63883	Human ubiquitously
c	75	8	40.0	10	1	AAH20566	Human MTR1 intron8
c	76	8	40.0	10	1	ABA06210	Human normal hepat
c	77	8	40.0	10	1	AAF41678	Yeast NORF gene SA
c	78	8	40.0	10	1	AAF35913	Yeast NORF gene SA
c	79	8	40.0	10	1	AAF33941	Yeast NORF gene SA
	80	8	40.0	10	1	AAF39304	Yeast NORF gene SA
	81	8	40.0	10	1	AAF36983	Yeast NORF gene SA
c	82	8	40.0	10	1	AAF38666	Yeast NORF gene SA
	83	8	40.0	10	1	AAF35236	Yeast NORF gene SA
	84	8	40.0	10	1	AAF41989	Yeast NORF gene SA
	85	8	40.0	10	1	AAF34855	Yeast NORF gene SA
c	86	8	40.0	10	1	AAF37464	Yeast NORF gene SA
c	87	8	40.0	10	1	AAF40963	Yeast NORF gene SA
c	88	8	40.0	10	1	AAD25091	Primer #18 used to
c	89	8	40.0	10	1	ABL01199	Human AKR1B1 gene
c	90	8	40.0	10	1	AAS98855	Colony stimulating
c	91	8	40.0	10	1	ABK96385	Human SA homologue
c	92	8	40.0	10	1	ABV78317	Human ribosomal pr
c	93	8	40.0	10	1	ABV78363	Human ribosomal pr
	94	8	40.0	10	1	ABK23667	Transcript tag DNA
	95	8	40.0	10	1	ABL57211	Primer extension o
c	96	8	40.0	10	1	ABK96547	Human PLAU gene, p
	97	8	40.0	10	1	AAS95484	Interleukin 5 (IL5
c	98	8	40.0	10	1	ADH75063	Photodamage detect
c	99	8	40.0	10	1	ADM77078	Photodamage marker

ALIGNMENTS

RESULT 1
AAA64908

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:23:31 ; Search time 0.001 Seconds
(without alignments)
20.560 Million cell updates/sec

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtccacctttttc 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 51 seqs, 514 residues

Total number of hits satisfying chosen parameters: 102

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 53 summaries

Database : fetchrge8.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	20	100.0	20	1	AR103288	ACCESSION:AR103288
c	2	10	50.0	11	1	AX624749	ACCESSION:AX624749
c	3	10	50.0	11	1	AX625581	ACCESSION:AX625581
c	4	10	50.0	11	1	AX632170	ACCESSION:AX632170
c	5	9.4	47.0	11	1	CQ832708	ACCESSION:CQ832708
	6	8.4	42.0	10	1	AR004345	ACCESSION:AR004345
c	7	8.4	42.0	10	1	AR004345	ACCESSION:AR004345
	8	8.4	42.0	10	1	AR006836	ACCESSION:AR006836
c	9	8.4	42.0	10	1	AR006836	ACCESSION:AR006836
c	10	8.4	42.0	10	1	AR227862	ACCESSION:AR227862
c	11	8.4	42.0	10	1	AR303457	ACCESSION:AR303457
c	12	8.4	42.0	10	1	AR303598	ACCESSION:AR303598
	13	8.4	42.0	10	1	AR303626	ACCESSION:AR303626
c	14	8.4	42.0	10	1	AX301603	ACCESSION:AX301603
c	15	8.4	42.0	10	1	BD086244	ACCESSION:BD086244
c	16	8.4	42.0	10	1	BD166548	ACCESSION:BD166548
c	17	8.4	42.0	10	1	BD166781	ACCESSION:BD166781
c	18	8	40.0	8	1	AX687084	ACCESSION:AX687084
	19	8	40.0	8	1	AX687085	ACCESSION:AX687085
c	20	8	40.0	9	1	AX497971	ACCESSION:AX497971
c	21	8	40.0	10	1	AR000247	ACCESSION:AR000247
c	22	8	40.0	10	1	AR150602	ACCESSION:AR150602
	23	8	40.0	10	1	BD240441	ACCESSION:BD240441
c	24	8	40.0	10	1	BD240561	ACCESSION:BD240561
	25	8	40.0	10	1	E27852	ACCESSION:E27852
	26	8	40.0	10	1	E27855	ACCESSION:E27855
c	27	8	40.0	10	1	E54835	ACCESSION:E54835
c	28	8	40.0	10	1	I83580	ACCESSION:I83580
c	29	8	40.0	10	1	I88948	ACCESSION:I88948
c	30	8	40.0	10	1	AR200483	ACCESSION:AR200483
c	31	8	40.0	10	1	AR303539	ACCESSION:AR303539
	32	8	40.0	10	1	AR303605	ACCESSION:AR303605
c	33	8	40.0	10	1	AR371285	ACCESSION:AR371285
c	34	8	40.0	10	1	AR392565	ACCESSION:AR392565
c	35	8	40.0	10	1	AR489506	ACCESSION:AR489506
c	36	8	40.0	10	1	AR491117	ACCESSION:AR491117
c	37	8	40.0	10	1	AX113035	ACCESSION:AX113035
c	38	8	40.0	10	1	AX152807	ACCESSION:AX152807
c	39	8	40.0	10	1	AX152808	ACCESSION:AX152808
c	40	8	40.0	10	1	AX152809	ACCESSION:AX152809
c	41	8	40.0	10	1	AX153055	ACCESSION:AX153055
c	42	8	40.0	10	1	AX153567	ACCESSION:AX153567
c	43	8	40.0	10	1	AX153619	ACCESSION:AX153619
c	44	8	40.0	10	1	AX301314	ACCESSION:AX301314
	45	8	40.0	10	1	AX301580	ACCESSION:AX301580
c	46	8	40.0	10	1	BD144707	ACCESSION:BD144707
c	47	8	40.0	10	1	BD161206	ACCESSION:BD161206
c	48	8	40.0	10	1	BD161252	ACCESSION:BD161252
	49	7.4	37.0	9	1	CQ759123	ACCESSION:CQ759123
c	50	7.4	37.0	9	1	AX668629	ACCESSION:AX668629
c	51	7.4	37.0	9	1	AX668630	ACCESSION:AX668630
c	52	7.4	37.0	9	1	AX668813	ACCESSION:AX668813
c	53	7.4	37.0	9	1	AX668814	ACCESSION:AX668814

ALIGNMENTS

RESULT 1
AR103288
LOCUS AR103288 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6087173.
ACCESSION AR103288
VERSION AR103288.1 GI:12814876
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Ackermann,E.J. and Cowsert,L.M.
TITLE Antisense modulation of X-linked inhibitor of apoptosis expression
JOURNAL Patent: US 6087173-A 8 11-JUL-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 TAGGACTTGTCCACCTTTTC 20
              ||||||||||||||||||||
Db          1 TAGGACTTGTCCACCTTTTC 20
```

RESULT 2
AX624749/c
LOCUS AX624749 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1790 from Patent WO02053774.
ACCESSION AX624749
VERSION AX624749.1 GI:28452690
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 1790 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:29:17 ; Search time 0.001 Seconds
(without alignments)
13.160 Million cell updates/sec

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtccacctttttc 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 34 seqs, 329 residues

Total number of hits satisfying chosen parameters: 68

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 34 summaries

Database : fetchrnpb8.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		12.4	62.0	15	1	US-10-698-689-126	Sequence 126, App
c 2		8.4	42.0	10	1	US-10-055-713-35	Sequence 35, Appl
c 3		8.4	42.0	10	1	US-10-055-711-39	Sequence 39, Appl
c 4		8.4	42.0	10	1	US-10-418-552-25	Sequence 25, Appl
c 5		8.4	42.0	10	1	US-10-293-222-317	Sequence 317, App
c 6		8.4	42.0	10	1	US-10-650-454-40	Sequence 40, Appl
c 7		8.4	42.0	10	1	US-10-470-180-35	Sequence 35, Appl
c 8		8	40.0	8	1	US-09-910-469-5	Sequence 5, Appli
9		8	40.0	8	1	US-09-910-469-6	Sequence 6, Appli
c 10		8	40.0	10	1	US-09-955-410-22	Sequence 22, Appl
c 11		8	40.0	10	1	US-09-983-210-26	Sequence 26, Appl
12		8	40.0	10	1	US-10-033-145-1859	Sequence 1859, Ap
c 13		8	40.0	10	1	US-10-033-145-1979	Sequence 1979, Ap
c 14		8	40.0	10	1	US-10-330-627-722	Sequence 722, App
c 15		8	40.0	10	1	US-10-330-627-723	Sequence 723, App
c 16		8	40.0	10	1	US-10-330-627-724	Sequence 724, App
c 17		8	40.0	10	1	US-10-330-627-970	Sequence 970, App
c 18		8	40.0	10	1	US-10-330-627-1482	Sequence 1482, Ap
c 19		8	40.0	10	1	US-10-330-627-1534	Sequence 1534, Ap
c 20		8	40.0	10	1	US-10-154-890-22	Sequence 22, Appl
c 21		8	40.0	10	1	US-10-293-222-28	Sequence 28, Appl
22		8	40.0	10	1	US-10-293-222-294	Sequence 294, App
c 23		7.4	37.0	9	1	US-09-989-789-2078	Sequence 2078, Ap
c 24		7.4	37.0	9	1	US-09-989-789-2079	Sequence 2079, Ap
c 25		7.4	37.0	9	1	US-09-989-789-2262	Sequence 2262, Ap
c 26		7.4	37.0	9	1	US-09-989-789-2263	Sequence 2263, Ap
c 27		7.4	37.0	9	1	US-09-990-186-2078	Sequence 2078, Ap
c 28		7.4	37.0	9	1	US-09-990-186-2079	Sequence 2079, Ap
c 29		7.4	37.0	9	1	US-09-990-186-2262	Sequence 2262, Ap
c 30		7.4	37.0	9	1	US-09-990-186-2263	Sequence 2263, Ap
c 31		7.4	37.0	9	1	US-09-989-994-2078	Sequence 2078, Ap
c 32		7.4	37.0	9	1	US-09-989-994-2079	Sequence 2079, Ap
c 33		7.4	37.0	9	1	US-09-989-994-2262	Sequence 2262, Ap
c 34		7.4	37.0	9	1	US-09-989-994-2263	Sequence 2263, Ap

ALIGNMENTS

RESULT 1
US-10-698-689-126
; Sequence 126, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsert, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 126
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-126

Query Match 62.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 0.53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          6 CTTGTCCACCTTTT 19
              |||| |||||||||
Db          2 CTTGACCACCTTTT 15
```

RESULT 2
US-10-055-713-35/c
; Sequence 35, Application US/10055713
; Publication No. US20030044957A1
; GENERAL INFORMATION:
; APPLICANT: JAMIESON, Andrew
; APPLICANT: LI, Guofu
; TITLE OF INVENTION: ZINC FINGER PROTEINS FOR DNA BINDING AND GENE
; TITLE OF INVENTION: REGULATION IN PLANTS
; FILE REFERENCE: 8325-0026 / S26-US1
; CURRENT APPLICATION NUMBER: US/10/055,713
; CURRENT FILING DATE: 2002-08-17
; PRIOR APPLICATION NUMBER: 60/263,445
; PRIOR FILING DATE: 2001-01-22
; PRIOR APPLICATION NUMBER: 60/290,716
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ZFP 1 target sequence
US-10-055-713-35

```
  Query Match            32.0%;  Score 6.4;  DB 1;  Length 8;
  Best Local Similarity   87.5%;  Pred. No. 0;
  Matches    7;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 CCACCTTT 18
              ||| ||||
Db          8 CCAGCTTT 1


RESULT 3
CF339699/c
LOCUS       CF339699                 8 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  RCL1--05-K22.g1 Regenerated callus lambda phage cDNA library (RCL1)
            Oryza sativa (japonica cultivar-group) cDNA clone RCL1--05-K22,
            mRNA sequence.
ACCESSION   CF339699
VERSION     CF339699.1  GI:33827769
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 8)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .8
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="RCL1--05-K22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli SOLR"
                     /clone_lib="Regenerated callus lambda phage cDNA library
                     (RCL1)"
                     /note="Vector: pBluescript SK(+); Site_1: SstI; Site_2:
                     XhoI; cDNA was inserted into lamda Uni-ZAP XR vector at 5'
                     end with SstI and 3' end with XhoI site. Callus was
                     induced on 2N6 media for 30 days and cultured for 36hrs on
                     regenerated media"

  Query Match            32.0%;  Score 6.4;  DB 1;  Length 8;
  Best Local Similarity   87.5%;  Pred. No. 0;
  Matches    7;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 CCACCTTT 18
              ||| ||||
Db          8 CCAGCTTT 1


RESULT 4
CF340204/c
LOCUS       CF340204                 8 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  RCL1--07-E15.g1 Regenerated callus lambda phage cDNA library (RCL1)
            Oryza sativa (japonica cultivar-group) cDNA clone RCL1--07-E15,
            mRNA sequence.
ACCESSION   CF340204
VERSION     CF340204.1  GI:33828768
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 8)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .8
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="RCL1--07-E15"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli SOLR"
                     /clone_lib="Regenerated callus lambda phage cDNA library
                     (RCL1)"
                     /note="Vector: pBluescript SK(+); Site_1: SstI; Site_2:
                     XhoI; cDNA was inserted into lamda Uni-ZAP XR vector at 5'
                     end with SstI and 3' end with XhoI site. Callus was
                     induced on 2N6 media for 30 days and cultured for 36hrs on
                     regenerated media"

  Query Match            32.0%;  Score 6.4;  DB 1;  Length 8;
  Best Local Similarity   87.5%;  Pred. No. 0;
  Matches    7;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 CCACCTTT 18
              ||| ||||
Db          8 CCAGCTTT 1


Search completed: November 15, 2004, 08:31:01
Job time : 0.001 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:27:34 ; Search time 0.001 Seconds
(without alignments)
14.400 Million cell updates/sec

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtccacctttttc 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 37 seqs, 360 residues

Total number of hits satisfying chosen parameters: 74

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 39 summaries

Database : fetchrni8.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	20	100.0	20	1	US-09-392-580-8	Sequence 8, Appli
	2	8.4	42.0	10	1	US-08-460-806-27	Sequence 27, Appl
c	3	8.4	42.0	10	1	US-08-460-806-27	Sequence 27, Appl
	4	8.4	42.0	10	1	US-08-325-630-27	Sequence 27, Appl
c	5	8.4	42.0	10	1	US-08-325-630-27	Sequence 27, Appl
c	6	8.4	42.0	10	1	US-08-388-353-191	Sequence 191, App
c	7	8.4	42.0	10	1	US-08-388-353-278	Sequence 278, App
c	8	8.4	42.0	10	1	US-08-488-551B-191	Sequence 191, App
c	9	8.4	42.0	10	1	US-08-488-551B-278	Sequence 278, App
c	10	8.4	42.0	10	1	US-09-008-303-3	Sequence 3, Appli
c	11	8.4	42.0	10	1	US-08-994-035C-1	Sequence 1, Appli
c	12	8.4	42.0	10	1	US-09-395-861-1	Sequence 1, Appli
c	13	8.4	42.0	10	1	US-09-508-753B-182	Sequence 182, App
c	14	8.4	42.0	10	1	US-09-508-753B-323	Sequence 323, App
	15	8.4	42.0	10	1	US-09-508-753B-351	Sequence 351, App
	16	8	40.0	8	1	US-08-859-954-208	Sequence 208, App
	17	8	40.0	8	1	US-08-859-954-230	Sequence 230, App
c	18	8	40.0	8	1	US-08-859-954-540	Sequence 540, App
c	19	8	40.0	10	1	US-08-686-116A-45	Sequence 45, Appl
c	20	8	40.0	10	1	US-08-685-484-45	Sequence 45, Appl
c	21	8	40.0	10	1	US-08-847-108-45	Sequence 45, Appl
c	22	8	40.0	10	1	US-08-686-113A-52	Sequence 52, Appl
c	23	8	40.0	10	1	US-08-847-095A-45	Sequence 45, Appl
c	24	8	40.0	10	1	US-08-088-661F-15	Sequence 15, Appl
c	25	8	40.0	10	1	US-08-150-156A-26	Sequence 26, Appl
c	26	8	40.0	10	1	US-08-108-591B-22	Sequence 22, Appl
c	27	8	40.0	10	1	US-08-686-114B-52	Sequence 52, Appl
c	28	8	40.0	10	1	US-09-508-753B-264	Sequence 264, App
	29	8	40.0	10	1	US-09-508-753B-330	Sequence 330, App
c	30	8	40.0	10	1	US-09-337-304-52	Sequence 52, Appl
c	31	8	40.0	10	1	US-08-468-719A-22	Sequence 22, Appl
c	32	8	40.0	10	1	US-08-462-977B-22	Sequence 22, Appl
	33	7	35.0	8	1	US-08-662-963-3	Sequence 3, Appli
	34	7	35.0	8	1	US-08-662-963-10	Sequence 10, Appl
	35	7	35.0	8	1	US-08-662-963-16	Sequence 16, Appl
	36	7	35.0	8	1	US-08-662-963-19	Sequence 19, Appl
	37	7	35.0	8	1	US-08-859-954-125	Sequence 125, App
c	38	7	35.0	8	1	US-08-859-954-245	Sequence 245, App
	39	7	35.0	8	1	US-08-859-954-384	Sequence 384, App

ALIGNMENTS

RESULT 1
US-09-392-580-8
; Sequence 8, Application US/09392580
; Patent No. 6087173
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF X-LINKED INHIBITOR OF APOPTOSIS EXPRESSIC
; FILE REFERENCE: RTS-0072
; CURRENT APPLICATION NUMBER: US/09/392,580
; CURRENT FILING DATE: 1999-09-09
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-392-580-8

Query Match 100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 TAGGACTTGTCCACCTTTTC 20
              ||||||||||||||||||||
Db          1 TAGGACTTGTCCACCTTTTC 20
```

RESULT 2
US-08-460-806-27
; Sequence 27, Application US/08460806
; Patent No. 5747241
; GENERAL INFORMATION:
; APPLICANT: MIYAMURA, TATSUO
; APPLICANT: SAITO, IZUMU
; APPLICANT: HARADA, SHIZUKO
; APPLICANT: HONDA, YOSHIKAZU
; TITLE OF INVENTION: DIAGNOSTIC REAGENT FOR HEPATITIS C
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,806
; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/325,630
; FILING DATE: 19-OCT-1994
; APPLICATION NUMBER: US 07/956,993

Set	Items	Description
S1	6121	(X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP OR (X-LINKED IAP) OR MIHA
S2	257315	ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT INTERFER? RNA) OR (RNA INTERFER?)
S3	10136532	CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S4	1886463	INFLAMMATORY OR INFLAMMATION
S5	1147	(FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S6	515	S1 AND S2
S7	436	S6 AND S3
S8	3487542	6 AND S3 OR S4 OR S5
S9	1888026	S6 AND S3 OR S4 OR S5
S10	26	S6 AND S4
S11	2	S6 AND S5
S12	0	9 RD
S13	3487542	6 AND S3 OR S4 OR S5
S14	1888026	S6 AND S3 OR S4 OR S5
S15	436	S6 AND S3
S16	165	RD (unique items)
S17	10	S16 NOT PY>2000

JOURNAL REGION: USA
JOURNAL SUBJECT: Business; General News
? S S16 NOT PY>2000
Processing
Processing
Processed 10 of 18 files ...
Processing
>>>One or more prefixes are unsupported
>>> or undefined in one or more files.
Processing
Processing
Completed processing all files
165 S16
94675125 PY>2000
S17 10 S16 NOT PY>2000
? T S17/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

17/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013237922 BIOSIS NO.: 200100409761
Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor **necrosis factor alpha-induced apoptosis of human synovial fibroblasts**
AUTHOR: Zhang Huang-Ge; Huang Ning; Liu Di; Bilbao Lupita; Zhang Xiaowu; Yang Pingar; Zhou Tong; Curiel David T; Mountz John D (Reprint)
AUTHOR ADDRESS: Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, 701 South 19th Street, LHRB 473, Birmingham, AL, 35294, USA**USA
JOURNAL: Arthritis and Rheumatism 43 (5): p1094-1105 May, 2000 2000
MEDIUM: print
ISSN: 0004-3591
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor **necrosis factor alpha-induced apoptosis of human synovial fibroblasts**

ABSTRACT: Objective. **Tumor** necrosis factor alpha (TNFalpha) increases the survival and proliferation of human rheumatoid arthritis (RA) cell...

...factor kappaB (IkappaB) dominant-negative adenovirus (AdCMVIkappaB-DN) and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were transfected in vitro, and...

...TNFalpha. There was no apoptosis after treatment with AdCMVIkappaB-DN in the absence of TNFalpha. **XIAP** is an inhibitor of apoptosis which was up-regulated by TNFalpha, and this up-regulation...

...greatly enhances apoptosis due to inhibition of an NF-kappaB-mediated antiapoptosis signaling pathway, and **XIAP** is a TNFalpha-inducible specific inhibitor of apoptosis in RA synovial cell lines. This and...
DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... **tumor** necrosis factor-alpha

17/K/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012897193 BIOSIS NO.: 200100069032
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression
AUTHOR: Kinoshita Hirokazu; Yoshikawa Hideshi; Shiki Kazuhiko; Hamada Yoshiki; Nakajima Yasuo; Tasaka Kachio (Reprint)
AUTHOR ADDRESS: Department of Parasitology and Immunology, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Yamanashi, 409-3898, Japan**Japan
JOURNAL: International Journal of Cancer 88 (6): p986-991 15 December, 2000 2000
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: escape from Fas/CD95-mediated apoptosis induced by immunosurveillance(NK cells and T cells) in **tumor** cells are correlated to **tumorigenicity** . Human osteosarcoma cell MG-63 constitutively expressed cell surface Fas antigen but was resistant to...
...form(FLIP-L), which was a novel anti-apoptotic protein and had a potency of **tumorigenicity** . CDDP down-regulated FLIP-L in a time-dependent manner in MG-63 cells but did not influence expression of other anti-apoptotic molecules such as **XIAP** , c-IAP-1, c-IAP-2, FADD or pro-caspase-8. Moreover, **antisense** oligonucleotide to FLIP-L confirmed that down-regulation of FLIP-L induced sensitization to Fas...
DESCRIPTORS:
...MAJOR CONCEPTS: **Tumor** Biology
CHEMICALS & BIOCHEMICALS: ... **XIAP** ;

17/K/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012810857 BIOSIS NO.: 200000529170
Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer **cells**
AUTHOR: Sasaki Hiromasa; Sheng YingLun; Kotsuji Fumikazu; Tsang Benjamin K (Reprint)
AUTHOR ADDRESS: Loeb Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, K1Y 4E9: btsang@lri.ca, Canada**Canada
JOURNAL: Cancer Research 60 (20): p5659-5666 October 15, 2000 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer **cells**

ABSTRACT: Cisplatin-centered chemotherapy is a key treatment for ovarian **cancer** , but resistance to chemotherapeutic agents remains a major cause of treatment failure. Multiple factors are...
...of this chemoresistance. Although it has been demonstrated that X-linked inhibitor of apoptosis protein (**Xiap**) prevents apoptosis by inhibiting effector caspases, if and how it is important in chemoresistance in ovarian **cancer** has not been studied. The effects of **Xiap** down-regulation and/or restoration of wild type p53 by recombinant adenovirus infection were examined on four ovarian epithelial **cancer** cell lines (C13*, A2780-s (wild type p53), A2780-cp (mutant p53), and SKOV3 (null p53)). Apoptosis and protein expression (e.g., **Xiap** , caspase-3, p53, MDM2, and p21waf1) were assessed by Hoechst 33258 stain and Western blot, respectively. We demonstrated that **Xiap** down-regulation following adenoviral **antisense** expression induces apoptosis in the wild-type p53 cells, but not in the mutated or null cells. **Xiap** down-regulation resulted in caspase-3 activation, caspase-mediated MDM2 processing, and p53 accumulation. Restoration...

...type p53 in the p53-mutated or -null cells significantly enhanced the proapoptotic effect of **Xiap** **antisense** expression. Down-regulation of **Xiap** induced apoptosis in chemoresistant ovarian **cancer** cells, a process dependent on p53 status.
DESCRIPTORS:
...MAJOR CONCEPTS: **Tumor** Biology
...ORGANISMS: chemoresistance, human ovarian **cancer** cell line, in-vitro model system, mutant p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, wild type p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, wild type p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, null p53 gene expression
CHEMICALS & BIOCHEMICALS: ...X-linked inhibitor of apoptosis downregulation role, caspase-mediated processing, **tumor** cell expression...

... **antisense** transfer-mediated downregulation, chemoresistant **tumor** cell apoptosis induction, recombinant adenovirus-mediated **antisense** transfer, **tumor** cell expression...

...X-linked inhibitor of apoptosis protein-induced **tumor** cell expression ...

...antineoplastic-drug, **tumor** cell resistance...
...X-linked inhibitor of apoptosis downregulation role, **tumor** cell accumulation

17/K/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012731647 BIOSIS NO.: 200000449960

Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death

AUTHOR: Holcik Martin; Yeh Chiaoli; Korneluk Robert G (Reprint); Chow Terry
AUTHOR ADDRESS: Molecular Genetics, Research Institute, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada** Canada
JOURNAL: Oncogene 19 (36): p4174-4177 24 August, 2000 2000
MEDIUM: print
ISSN: 0950-9232
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death

ABSTRACT: Inhibitory regulators of apoptosis play a critical role in the responsiveness of **tumour** cells to cytotoxic agents. The X-linked inhibitor of apoptosis protein (**XIAP**) is a member of a novel family of Inhibitor of Apoptosis (IAP) proteins. Here we show that acute low dose ionizing irradiation results in the translational upregulation of **XIAP** that correlates with an increased resistance to radiation in non-small cell lung **carcinoma** . This upregulation is mediated by an internal ribosome binding mechanism via an IRES element located within a **XIAP** 5' UTR. Transient overexpression of **XIAP** rendered human **carcinoma** cells resistant to low dose gamma-irradiation. By contrast, the **antisense** targeting of **XIAP** resulted in increased cell death following irradiation advocating a distinct role for **XIAP** in radiation resistant phenotype of human **cancers** .
DESCRIPTORS:
...MAJOR CONCEPTS: **Tumor** Biology
DISEASES: **cancer** --...

...non-small cell lung **carcinoma** --
...MESH TERMS: **Carcinoma** , Non-Small-Cell Lung (MeSH
CHEMICALS & BIOCHEMICALS: ... **X-linked inhibitor of apoptosis** ...

... **antisense** targeting, translation upregulation...

... **tumor** cell responsiveness

17/K/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012655181 BIOSIS NO.: 200000373494
Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression
AUTHOR: Fulda Simone; Meyer Eric; Debatin Klaus-Michael (Reprint)
AUTHOR ADDRESS: University Children's Hospital, Prittwitzstrasse 43, D-89075, Ulm, Germany**Germany
JOURNAL: Cancer Research 60 (14): p3947-3956 July 15, 2000 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: both molecules have a high turnover rate. Selective down-regulation of FLIP expression by FLIP **antisense** oligonucleotides sensitized for CD95-induced apoptosis. Reduction of FLIP levels resulted in undetectable amounts of...

...sensitized for subsequent CD95 stimulation compared with cells without pretreatment. CHX or ActD also reduced **XIAP** expression and similarly sensitized for **tumor** necrosis factor-related apoptosis-inducing ligand- or **tumor** necrosis factor-alpha-induced apoptosis. Because blockade of death receptor triggering by FLIP overexpression has recently been implicated in **tumorigenesis** and treatment resistance in vivo, strategies to inhibit FLIP expression, e.g., by metabolic inhibitors, may prove to be a useful complementary tool for the treatment of **cancer** .
DESCRIPTORS:
...MAJOR CONCEPTS: **Tumor** Biology
CHEMICALS & BIOCHEMICALS: ...metabolic inhibitor drug sensitization, **tumor** cell apoptosis induction...

...metabolic inhibitor drug-induced downregulation, **tumor** cell, expression...

17/K/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012599835 BIOSIS NO.: 200000318148
Apoptosis and chemoresistance in human ovarian cancer : **Is** Xiap **a determinant?**
AUTHOR: Li Julang; Sasaki Hiromasa; Sheng Ying Lun; Schneiderman Danielle; Xiao Chao Wu; Kotsuji Fumikazu; Tsang Benjamin K (Reprint)
AUTHOR ADDRESS: Department of Obstetrics and Gynaecology, Ottawa Hospital, 1053 Carling Avenue, Civic Campus, Ottawa, ON, K1Y 4E9, Canada**Canada
JOURNAL: Biological Signals and Receptors 9 (2): p122-130 March-April, 2000 2000
MEDIUM: print
ISSN: 1422-4933
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Apoptosis and chemoresistance in human ovarian cancer : **Is** Xiap **a determinant?**

ABSTRACT: Cisplatin-induced apoptosis in epithelial ovarian **cancer** cells is in part a consequence of suppressed **Xiap** expression and upregulation of the Fas/FasL system. Changes in the expression of these 'cell...
...genes lead to activation of caspase-3, and cleavage of MDM2 and FAK. Failure of **cancer** cells to maintain a balance in the expression of these genes in favor of apoptotic cell death may be an important factor of chemoresistance. **Xiap** may be a novel target for gene therapy of human ovarian epithelial **cancer** and, dependent on P53 status, expression of **Xiap** **antisense** alone or in combination with wild-type P53 sense may offer a new approach for the treatment of the chemoresistant **cancer** .

DESCRIPTORS:
DISEASES: ovarian **cancer** --

17/K/7 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

14387430 PMID: 10381630
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.
Wagenknecht B; Glaser T; Naumann U; Kugler S; Isenmann S; Bahr M; Korneluk R; Liston P; Weller M
Laboratory of Molecular Neuro-Oncology, Hoppe-Seyler-Strasse 3, Germany.
Cell death and differentiation (ENGLAND) Apr 1999, 6 (4) p370-6, ISSN 1350-9047 Journal Code: 9437445
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.
... via direct inhibition of caspases. Here, we report that human malignant glioma cell lines express **XIAP** , HIAP-1 and HIAP-2 mRNA and proteins. NAIP was not expressed. IAP proteins were...

... exposure to CD95L and a protein synthesis inhibitor, CHX, to acquire sensitivity to apoptosis. Adenoviral **XIAP** gene transfer blocked caspase 8 and 3 processing in both cell lines in the absence of CHX. Apoptosis was blocked in the absence and in the presence of CHX. However, **XIAP** failed to block caspase 8 processing in LN-229 cells in the presence of CHX. There was considerable overlap of the effects of **XIAP** on caspase processing with those of BCL-2 and the viral caspase inhibitor crm-A...

... of these cells to apoptotic stimuli that directly target caspases, including radiochemotherapy and immune-mediated **tumor** cell lysis.
; Adenoviridae--genetics--GE; Antigens, CD95--genetics--GE; **Antisense** Elements (Genetics); Caspases--metabolism--ME; Gene Transfer Techniques; Neoplasm Proteins--genetics--GE; Proteins--genetics--GE; **Tumor** Cells, Cultured--enzymology--EN; **Tumor** Cells, Cultured--pathology--PA; **Tumor** Cells, Cultured--physiology--PH
Chemical Name: Antigens, CD95; **Antisense** Elements (Genetics); IAP-like protein, vertebrate; Neoplasm Proteins; Proteins; Caspases

17/K/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130137344 CA: 130(11)137344n PATENT
XAF proteins interacting with IAPs (inhibitors of apoptosis proteins) and the genes encoding them and their use in the therapeutic regulation of apoptosis
INVENTOR(AUTHOR): Korneluk, Robert; Tamai, Katsuyuki; Liston, Peter; Mackenzie, Alexander E.; Baird, Stephen
LOCATION: Can.,
ASSIGNEE: University of Ottawa

PATENT: European Pat. Appl. ; EP 892048 A2 DATE: 19990120
APPLICATION: EP 98113003 (19980713) *US 52402 (19970714) *US 54491 (19970801) *US 56338 (19970818)
PAGES: 101 pp. CODEN: EPXXDW LANGUAGE: English CLASS: C12N-015/12A; C12N-015/11B; C07K-014/47B; C12N-015/85B; C12N-005/10B; A01K-067/027B; G01N-033/50B; A61K-038/17B; A61K-048/00B; C12Q-001/68B; C12P-021/08B
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO

17/K/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129197985 CA: 129(16)197985m PATENT
Detection and modulation of protein inhibitors of apoptosis (IAPs) and neuronal apoptosis-inhibiting protein (NAIP) for the diagnosis and treatment of proliferative disease
INVENTOR(AUTHOR): Korneluk, Robert; MacKenzie, Alexander E.; Liston, Peter; Baird, Stephen; Tsang, Benjamin; Pratt, Christine
LOCATION: Can.,
ASSIGNEE: University of Ottawa
PATENT: PCT International ; WO 9835693 A2 DATE: 19980820
APPLICATION: WO 98IB781 (19980213) *US 800929 (19970213)
PAGES: 148 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/17A; A61K-031/70B; A61K-039/395B; C12N-015/11B; C12Q-001/68B; G01N-033/50B; G01N-033/574B; A01K-067/027B; C12N-015/00B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH ; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

17/K/10 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

14624714 PASCAL No.: 00-0295143
Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor **necrosis factor alpha -induced apoptosis of human synovial fibroblasts**
ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU; CURIEL D T; MOUNTZ J D
University of Alabama at Birmingham, United States; Gene Therapy Program, Birmingham, Alabama, United States; University of Alabama at Birmingham, Birmingham, Alabama, United States; Veterans Administration Medical Center, Birmingham, Alabama, United States
Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
Language: English

Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor **necrosis factor alpha -induced apoptosis of human synovial fibroblasts**

Objective. **Tumor** necrosis factor a (TNFa) increases the survival and proliferation of human rheumatoid arthritis (RA) cell...
... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence of TNFa. **XIAP** is an inhibitor of apoptosis which was up-regulated by TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific inhibitor of apoptosis in RA synovial cell lines. This and...

English Descriptors: Rheumatoid arthritis; Treatment; Chemotherapy; Gene therapy; Mechanism of action; Inhibition; Translocation; Apoptosis; Cell death; **Tumor** necrosis factor alpha ; Fibroblast; Synovial membrane; In vitro; Human; Tissue culture; Chronic; Transcription factor NF...

French Descriptors: Polyarthrite rhumatoide; Traitement; Chimiotherapie; Therapie genique; Mecanisme action; Inhibition; Translocation; Apoptose; Mort cellulaire; Facteur necrose **tumorale** alpha ; Fibroblaste; Synoviale; In vitro; Homme; Culture tissu; Chronique; Facteur transcription NF kappa B

Spanish Descriptors: Poliartritis reumatoidea; Tratamiento; Quimioterapia; Terapia genica; Mecanismo accion; Inhibicion; Translocacion; Apoptosis; Muerte celular; Factor necrosis **tumoral** alpha ; Fibroblasto; Sinovial; In vitro; Hombre; Cultivo tejido; Cronico
?

18	6121	(X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP OR (X-LINKED IAP) OR MIHA
S19	257315	ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT INTERFER? RNA) OR (RNA INTERFER?)
S20	10136532	CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S21	1886463	INFLAMMATORY OR INFLAMMATION
S22	1147	(FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S23	515	S18 AND S19
S24	436	S23 AND S20
S25	3487542	6 AND S20 OR S21 OR S22
S26	1888026	S23 AND S20 OR S21 OR S22
S27	26	S23 AND S21
S28	2	S23 AND S22
S29	0	9 RD
S30	3487542	6 AND S20 OR S21 OR S22
S31	1888026	S23 AND S20 OR S21 OR S22
S32	436	S23 AND S20
S33	165	RD (unique items)
S34	10	S33 NOT PY>2000

Set	Items	Description
S1	6121	(X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP OR (X-LINKED IAP) OR MIHA
S2	257315	ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT INTERFER? RNA) OR (RNA INTERFER?)
S3	10136532	CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S4	1886463	INFLAMMATORY OR INFLAMMATION
S5	1147	(FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S6	515	S1 AND S2
S7	436	S6 AND S3
S8	3487542	6 AND S3 OR S4 OR S5
S9	1888026	S6 AND S3 OR S4 OR S5
S10	26	S6 AND S4
S11	2	S6 AND S5
S12	0	9 RD
S13	3487542	6 AND S3 OR S4 OR S5
S14	1888026	S6 AND S3 OR S4 OR S5
S15	436	S6 AND S3
S16	165	RD (unique items)
S17	10	S16 NOT PY>2000
S18	6121	(X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP OR (X-LINKED IAP) OR MIHA
S19	257315	ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT INTERFER? RNA) OR (RNA INTERFER?)
S20	10136532	CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S21	1886463	INFLAMMATORY OR INFLAMMATION
S22	1147	(FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S23	515	S18 AND S19
S24	436	S23 AND S20
S25	3487542	6 AND S20 OR S21 OR S22
S26	1888026	S23 AND S20 OR S21 OR S22
S27	26	S23 AND S21
S28	2	S23 AND S22
S29	0	9 RD
S30	3487542	6 AND S20 OR S21 OR S22
S31	1888026	S23 AND S20 OR S21 OR S22
S32	436	S23 AND S20
S33	165	RD (unique items)
S34	10	S33 NOT PY>2000

? T S27/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

27/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013914248 BIOSIS NO.: 200200507759
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
AUTHOR: Bureau Fabrice (Reprint); Seumois Gregory; Jaspar Fabrice; Vanderplasschen Alain; Detry Bruno; Pastoret Paul-Pierre; Louis Renaud; Lekeux Pierre
AUTHOR ADDRESS: Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, Bat. B42, B-4000, Liege, Belgium** Belgium
JOURNAL: Journal of Allergy and Clinical Immunology 110 (3): p443-449 September, 2002 2002
MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...**survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation
...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-xL, or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .
DESCRIPTORS:
DISEASES: allergic **inflammation** --
CHEMICALS & BIOCHEMICALS: ...X-inhibitor of apoptosis protein { **XIAP** };

27/K/2 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

19160771 Document Delivery Available: 0002235546
ISSN: 0021-9258
JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY , 2004
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...kappa B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in **inflammatory** arthritis. Dai S; Hirayama T; Abbas S; Abu-Amer Y. Washington Univ, Dept Orthoped Surg...

...000223554600075

P. 37982-37996. Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping **antisense** mRNA transcript. Robb GB; Carson AR; Tai SC; Fish JE; Singh S; Yamada T; Scherer...Geneva//Switzerland/. English. ARTICLE. 77 REFERENCES. ABSTRACT AVAILABLE. Document Delivery no: 000223554600028

P. 37431-37435. **RNAi** -based analysis of CAP, Cbl, and CrkII function in the regulation of GLUT4 by insulin...processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing **XIAP** . Seong YM; Choi JY; Park HJ; Kim KJ; Ahn SG; Seong GH; Kim IK; Kang...

27/K/3 (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

18293256 Document Delivery Available: 0002208704
ISSN: 0021-9258
JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY , 2004
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...AVAILABLE. Document Delivery no: 000220870400117

P. 18091-18097. In vivo chromatin remodeling events leading to **inflammatory** gene transcription under diabetic conditions. Miao F; Gonzalo IG; Lanting L; Natarajan R. City Hope...

...Determination of the role of the human RNase H1 in the pharmacology of DNA-like **antisense** drugs. Wu HJ; Lima WF; Zhang H; Fan A; Sun H; Crooke ST. ISIS Pharmaceut...DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of **XIAP** and livin in HeLa cells. Yang QH; Du CY. Stowers Inst Med Res, 1000E 50th...

27/K/4 (Item 3 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

16540078 Document Delivery Available: 0001841087
ISSN: 1078-0432
JOURNAL: CLINICAL CANCER RESEARCH , 2003
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...English. ARTICLE. 25 REFERENCES. ABSTRACT AVAILABLE. Document Delivery no: 000184108700017

P. 2510-2519. Efficacy of **antisense** morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase... AVAILABLE. Document Delivery no: 000184108700052

P. 2798-2806. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits **inflammatory** response and tumor growth in vivo. Place AE; Suh N; Williams CR; Risingsong R; Honda...Bloomington//MN/. English. ARTICLE. 46 REFERENCES. ABSTRACT AVAILABLE. Document Delivery no: 000184108700055

P. 2826-2836. **Antisense** oligonucleotides targeting **XIAP** induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in...

...Utrecht//Netherlands/. English. ARTICLE. 40 REFERENCES. ABSTRACT AVAILABLE. Document Delivery no: 000184108700058

P. 2856-2865. **Antisense** Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis...

27/K/5 (Item 4 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

14656002 Document Delivery Available: 000177936900015 References: 31
TITLE: CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
AUTHOR(S): Bureau F (REPRINT); Seumois G; Jaspar F; Vanderplasschen A; Detry B; Pastoret PP; Louis R; Lekeux P
CORPORATE SOURCE: Univ Liege, Dept Physiol, Bat B42/B-4000 Liege//Belgium/ (REPRINT); Univ Liege, Dept Physiol, /B-4000 Liege//Belgium/; Univ Liege, Dept Immunol Vaccinol, /B-4000 Liege//Belgium/; Univ Liege, Dept Pneumol, /B-4000 Liege//Belgium/
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, V110, N3 (SEP), P443-449
GENUINE ARTICLE#: 592KM
PUBLISHER: MOSBY, INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
ISSN: 0091-6749
LANGUAGE: English DOCUMENT TYPE: ARTICLE (ABSTRACT AVAILABLE)

...**TITLE: survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation

...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x(L) and Bfl...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides.

Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .

27/K/6 (Item 5 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

12111850
ISSN: 0021-9258
JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY , 2000
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...Div, /E Melbourne/Vic 3000/Australia/. English. ARTICLE. 33 REFERENCES. ABSTRACT AVAILABLE

P. 32077-32088. **Inflammatory** versus proliferative processes in epidermis - Tumor necrosis factor alpha induces K6b keratin synthesis through a...Dept Biomed Engn, /Memphis//TN/38152. English. ARTICLE. 50 REFERENCES. ABSTRACT AVAILABLE

P. 31733-31738. **XIAP** regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. Datta R; ...D-35033 Marburg//Germany/. English. ARTICLE. 58 REFERENCES. ABSTRACT AVAILABLE

P. 32281-32288. Expression of **antisense** to integrin subunit beta(3) inhibits microvascular endothelial cell capillary tube formation in fibrin. Dallabrida...

27/K/7 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

10980082 Genuine Article#: 592KM No. References: 31
Title: CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
Author(s): Bureau F (REPRINT) ; Seumois G; Jaspar F; Vanderplasschen A; Detry B; Pastoret PP; Louis R; Lekeux P
Corporate Source: Univ Liege,Fac Vet Med, Dept Physiol,Bat B42/B-4000 Liege//Belgium/ (REPRINT); Univ Liege,Fac Vet Med, Dept Physiol,B-4000 Liege//Belgium/; Univ Liege,Fac Vet Med, Dept Immunol Vaccinol,B-4000 Liege//Belgium/; Univ Liege,Fac Med, Dept Pneumol,B-4000 Liege//Belgium/
Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, V110, N3 (SEP) , P443-449
ISSN: 0091-6749 Publication date: 20020900
Publisher: MOSBY, INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

...**Title: survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation
...Abstract: of the inhibitor of apoptosis protein (IAP) family, namely

cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x(L) and Bfl...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides.

Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .

27/K/8 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11994848 PMID: 12209092

CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation .

Bureau Fabrice; Seumois Gregory; Jaspar Fabrice; Vanderplasschen Alain; Detry Bruno; Pastoret Paul-Pierre; Louis Renaud; Lekeux Pierre
Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Belgium.

Journal of allergy and clinical immunology (United States) Sep 2002, 110 (3) p443-9, ISSN 0091-6749 Journal Code: 1275002
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

...survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation .
... of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x(L) and Bfl...
... staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides. RESULTS: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

... Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

... through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .

...; IM; Cell Survival; Cells, Cultured; Eosinophilia--immunology--IM; Eosinophils--cytology--CY; Hypersensitivity, Immediate--pathology--PA; **Inflammation** --immunology--IM; Sputum--cytology--CY

27/K/9 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141307497 CA: 141(19)307497m PATENT
Use of caspase inhibitors as antiviral agents, and test system for their discovery
INVENTOR(AUTHOR): Ludwig, Stefan; Planz, Oliver; Sedlacek, Hans-Harald; Pleschka, Stephan
LOCATION: Germany,
ASSIGNEE: Medinnova Gesellschaft fur Medizinische Innovationen aus Akademischer Forschung m.b.H.
PATENT: PCT International ; WO 200485682 A2 DATE: 20041007
APPLICATION: WO 2004DE646 (20040324) *DE 10313636 (20030326)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: C12Q-001/70A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

27/K/10 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11770551 EMBASE No: 2002339725
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
Bureau F.; Seumois G.; Jaspar F.; Vanderplasschen A.; Detry B.; Pastoret P.-P.; Louis R.; Lekeux P.
Dr. F. Bureau, Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, B-4000 Liege Belgium
Journal of Allergy and Clinical Immunology (J. ALLERGY CLIN. IMMUNOL.) (United States) 2002, 110/3 (443-449)
CODEN: JACIB ISSN: 0091-6749
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 31

...survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation

...of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xSUBL and Bfl-1...
...staining with propidium iodide and FITC-conjugated annexin-V, c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-xSUBL, or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .
DRUG DESCRIPTORS:
propidium iodide; fluorescein isothiocyanate; lipocortin 5; **antisense** oligonucleotide; RNA--endogenous compound--ec; unclassified drug
MEDICAL DESCRIPTORS:
*allergic asthma--etiology--et; * **inflammation** --etiology--et; *eosinophil

27/K/11 (Item 1 from file: 71)

02138183 2002219133
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
Bureau F.; Seumois G.; Jaspar F.; Vanderplasschen A.; Detry B.; Pastoret P.-P.; Louis R.; Lekeux P.
ADDRESS: Dr. F. Bureau, Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, B-4000 Liege, Belgium
Journal: Journal of Allergy and Clinical Immunology, 110/3 (443-449), 2002 , United States
CODEN: JACIB
ISSN: 0091-6749
DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 31

DESCRIPTORS:
Allergy; Apoptosis; Asthma; Atopy; CD40; Eosinophils; Granulocytes; **Inflammation** ; Neutrophils

CLASSIFICATION CODE AND DESCRIPTION:
86.3.3.9 - IMMUNOLOGY AND INFECTIOUS DISEASES / CELLS OF THE IMMUNE SYSTEM / T Lymphocytes / General functions and activation
86.3.9 - IMMUNOLOGY AND INFECTIOUS DISEASES / CELLS OF THE IMMUNE SYSTEM / Eosinophil Leucocytes
86.8.1.4 - IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNE RESPONSE DISORDERS / Acute **Inflammation** , Immediate Hypersensitivity, Anaphylaxis / Diagnosis and therapy
89.2.5.4 - CELL AND DEVELOPMENTAL BIOLOGY / CELL GROWTH AND DIVISION / Cellular Senescence and Death / Death (apoptosis

...**survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation

...of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xSUBL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V, c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results:

Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...
...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-xSUBL, or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .

DESCRIPTORS:
Allergy; Apoptosis; Asthma; Atopy; CD40; Eosinophils; Granulocytes; **Inflammation** ; Neutrophils

CLASSIFICATION CODE AND DESCRIPTION:
...Acute **Inflammation** , Immediate Hypersensitivity, Anaphylaxis...

27/K/12 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

15809300 PASCAL No.: 02-0525803
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
BUREAU Fabrice; SEUMOIS Gregory; JASPAR Fabrice; VANDERPLASSCHEN Alain; DETRY Bruno; PASTORET Paul-Pierre; LOUIS Renaud; LEKEUX Pierre
Department of Physiology, Faculty of Veterinary Medicine, Department of Pneumology, Faculty of Medicine, University of Liege, Liege, Belgium; Department of Immunology/Vaccinology, Faculty of Veterinary Medicine, Department of Pneumology, Faculty of Medicine, University of Liege, Liege, Belgium
Journal: Journal of allergy and clinical immunology, 2002, 110 (3) 443-449
Language: English

...survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
... of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x SUB L and...

... staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

... Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-x SUB L , or Bfl-1/A1 expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

... through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .

English Descriptors: Asthma; Allergy; Atopy; Human; Pathogenesis; Eosinophil; **Inflammation** ; Granulocyte; Apoptosis; Blood; Sputum; Flow cytometry; Immunoblotting assay

French Descriptors: Asthme; Allergie; Atopie; Homme; Pathogenie; Eosinophile; **Inflammation** ; Granulocyte; Apoptose; Sang; Expectoration; Cytometrie flux; Methode immunoblotting; Antigene CD40; Proteine IAP

27/K/13 (Item 2 from file: 144)
DIALOG(R)File 144:Pascal

14624714 PASCAL No.: 00-0295143
Gene therapy that inhibits nuclear translocation of nuclear factor KB results in tumor necrosis factor alpha -induced apoptosis of human synovial fibroblasts
ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU; CURIEL D T; MOUNTZ J D
University of Alabama at Birmingham, United States; Gene Therapy Program, Birmingham, Alabama, United States; University of Alabama at Birmingham, Birmingham, Alabama, United States; Veterans Administration Medical Center, Birmingham, Alabama, United States
Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
Language: English

... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence of TNFa. **XIAP** is an inhibitor of apoptosis which was up-regulated by TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific inhibitor of apoptosis in RA synovial cell lines. This and...
Broad Descriptors: Diseases of the osteoarticular system; **Inflammatory** joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme osteoarticulaire pathologie; Rhumatisme inflammatoire; Immunopathologie; Maladie autoimmune; Cytokine...

27/K/14 (Item 1 from file: 991)
DIALOG(R)File 991:NewsRoom 2004 Jan 1-2004/Jul 31

0836083099 16L82K4U
POSTERS: SIGNAL TRANSDUCTION (NOT INSULIN ACTION)-CYTOKINES AND APOPTOSIS
Cao, Wen M
Murao, Koji
Imachi, Hitomi
Yu, Xiao
Et al
Diabetes, pA442

Tuesday, June 1, 2004
JOURNAL CODE: AHKF LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Trade Journal ISSN: 0012-1797
WORD COUNT: 3,312

...protein bound the PRCE by EMSA and was identified by super shift assay. Finally, PREB- **siRNA** , that inhibited the PREB expression, significantly decreased the effect of glucose on MCP-1 promoter...

...FN mRNA and protein expression in a dose-dependent manner. HUVECs were then transfected with **SiRNA** targeted to oncofetal FN. The transfected endothelial cells were cultured in low (5 mmol/L...
...glucose caused upregulation of VEGF mRNA levels in the negative control transfected cells. Transfection with **SiRNA** targeted to oncofetal FN completely abolished glucose-induced VEGF mRNA expression. Endothelial cells were then...

...K. KIM. New Haven, CT

We have previously shown that acute pre-treatment of anti- **inflammatory** cytokine, interleukin (IL)-10, prevented insulin resistance associated with 5-hour lipid infusion, and the...

...Research

1859-P

Cytoprotection of Pancreatic [beta] Cells by Co-Overexpression of Bcl-2 and **XIAP** Genes Blocking TRAIL-Mediated Death-Signal Transduction Pathways

DAWEI OU, XIAJIE WANG, DANIEL L. METZGER...

...investigated the inhibitory effects of Bcl-2 and the X-linked inhibitor of apoptosis protein (**XIAP**) on TNF-related apoptosis-inducing ligand (TRAIL)-induced human [beta]-cell destruction. A panel of...

...type NES2Y and CM cells and the vector transfectants (P<0.0002 to 0.01). **XIAP** -overexpressed NES2Y and CM cells were developed by exposing the cells to an infectious **XIAP** recombinant adenovirus (AdXIAP) at MOI 10. [beta] cells infected with AdLacz were used as controls...

...AdXIAP were much less than that observed in cells transfected with either Bcl-2 or **XIAP** alone (P<0.0004 to 0.04). Overexpression of Bcl-2 and/or **XIAP** by gene transfection inhibited TRAIL-induced activation of caspases and TRAIL-mediated damage of mitochondrial...

...these cells suggesting the major mechanisms of regulation. These results indicated that Bcl-2 and **XIAP** are important components of the signal transduction pathways that regulate TRAIL-induced human [beta]-cell death and that there may be novel therapeutic potential of Bcl-2 and **XIAP** co-overexpression [beta] cells in type 1 diabetes.

1860-P

Protein Kinase C alpha Activation...

27/K/15 (Item 2 from file: 991)

DIALOG(R)File 991:NewsRoom 2004 Jan 1-2004/Jul 31

0803005993 16J605V8
OTHER NEWS TO NOTE
BioWorld Today, v15
Tuesday, March 30, 2004
JOURNAL CODE: ARME LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newsletter SECTION HEADING: 60 ISSN: 1541 0595
WORD COUNT: 1,824

Aegera Therapeutics Inc., of Montreal, began Phase I trials of AEG35156/GEM640, an **antisense** inhibitor of x-linked inhibitor of apoptosis protein (**XIAP**), in collaboration with Cancer Research UK. AEG35156 is a second-generation **antisense** oligonucleotide, designed to reduce high levels of **XIAP** in cancer cells and enable cell death. The initial trial is in patients with advanced...

...agreement with Funakoshi Ltd., of Tokyo, related to RNAx's services for the validation of **siRNA** oligonucleotides and genetic targets based on RNA interference technology. Funakoshi will act as exclusive agent...

...applications for endothelial differentiation gene (Edg) receptors 1 through 7 and their use in cancer, **inflammation** and other diseases. Ceretek also transferred its cell lines incorporating chimeric Edg receptors for screening...

27/K/16 (Item 1 from file: 992)
DIALOG(R)File 992:NewsRoom 2003

0589510171 162V09XU
Research and Markets: Targeting endogenous inhibitors of apoptosis: Opportunities for the treatment of cancer, stroke and MS
M2 Communications
Tuesday, February 11, 2003
JOURNAL CODE: ALPP LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newswire
WORD COUNT: 1,549

...Proteins") family. This field has grown exponentially since 1995 and continues to do so. Although **XIAP** and survivin remain the better known members of this family, 8 human IAPs have now...

...contributed much of the data surrounding one of the most promising targets from this family, **XIAP** .

Dr Jon Goldhill: Dr Jon Goldhill has over 10 years of academic and industrial research...

...management at the French pharmaceutical giants, Sanofi-Synthelabo. Focussing on a variety of indications including **inflammatory** disorders, GI disease, Urological conditions and cancer, Dr Goldhill was responsible for target identification and...

...apoptosis inhibitory protein; NAIP) BIRC2 (API1; HIAP2; cIAP1; MIHB) BIRC3 (API2; HIAP1; cIAP2; MIHC) BIRC4 (**XIAP** ; API3; **MIHA** ; ILP) BIRC5

(Survivin; API4; TLAP) BIRC6 (Apollon; BRUCE) BIRC7 (MLIAP; KIAP; Livin) BIRC8: (ILP-2...

...13-PE38 apolizumab alvocidib indisulam combretastatin A-4 Profiles of IAP-related molecules HIAP-1 **antisense** **XIAP** inhibitors AEG-161 Apoptosis inhibitors Trends in apoptosis inhibitors Apoptosis inhibitors in development Profiles of...

27/K/17 (Item 1 from file: 20)
DIALOG(R)File 20:Dialog Global Reporter

27495364 (USE FORMAT 7 OR 9 FOR FULLTEXT)
Research and Markets: Targeting endogenous inhibitors of apoptosis: Opportunities for the treatment of cancer, stroke and MS
M2 PRESSWIRE
February 11, 2003
JOURNAL CODE: WMPR LANGUAGE: English RECORD TYPE: FULLTEXT
WORD COUNT: 1471

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... Proteins") family. This field has grown exponentially since 1995 and continues to do so. Although **XIAP** and survivin remain the better known members of this family, 8 human IAPs have now...

... contributed much of the data surrounding one of the most promising targets from this family, **XIAP** .
Dr Jon Goldhill: Dr Jon Goldhill has over 10 years of academic and industrial research...

... management at the French pharmaceutical giants, Sanofi-Synthelabo. Focussing on a variety of indications including **inflammatory** disorders, GI disease, Urological conditions and cancer, Dr Goldhill was responsible for target identification and...

... apoptosis inhibitory protein; NAIP) BIRC2 (API1; HIAP2; cIAP1; MIHB) BIRC3 (API2; HIAP1; cIAP2; MIHC) BIRC4 (**XIAP** ; API3; **MIHA** ; ILP) BIRC5 (Survivin; API4; TLAP) BIRC6 (Apollon; BRUCE) BIRC7 (MLIAP; KIAP; Livin) BIRC8: (ILP-2...

... 13-PE38 apolizumab alvocidib indisulam combretastatin A-4 Profiles of IAP-related molecules HIAP-1 **antisense** **XIAP** inhibitors AEG-161 Apoptosis inhibitors Trends in apoptosis inhibitors Apoptosis inhibitors in development Profiles of...

27/K/18 (Item 1 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00241838

CANCER: 1.1 THIS MONTH'S HIGHLIGHTS

Main Title: PHARMAWATCH
Pub. Date: July 23, 2003
Source: DATAMONITOR

Telephone: +44 20 7675 7000
Word Count: 3689 (2 pp.)
Language: English

Features: TABLE
Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Accentia Inc ; American Association for Cancer Research ; American Cancer Society ; American Gastroenterological Association ; American Society of Clinical Oncology ; American Society of Hematology ; American Urological Association ; Amgen ; AnorMed ; Ariad Pharmaceuticals ; AstraZeneca ; Aton Pharma ; ARIA ; AVI BioPharma ; Bayer ; Beatson Cancer Institute ; Beatson Oncology Centre ; Biogen Idec Inc ; Biologics License Application ; Biomira ; Biovest International ; BioTransplant ; Bone Metastases ; Breast Cancer Center of Excellence ; Bristol Myers Squibb ; British Biotech ; BMS/Celltech ; BMY ; Cancer Treatment ; Case Western Reserve University School of Medicine ; Catholic University ; Cell Therapeutics ; Celltech ; Chugai ; Committee for Proprietary Medicinal ; Corixa Corporation ; Department of Defense ; Drug Safety Monitoring Committee ; DNA ; Eli Lilly and Company ; Equal ; European Agency for the Evaluation of Medicinal Products ; European Commission ; European Committee on Proprietary Medicinal ; European Neurological Society ; Genentech ; Genta ; Georgetown University Medical Center ; German Federal Institute for Drugs ; GlaxoSmithKline ; GASTRO ; GTx Inc ; GTAC ; GTI ; Idec Biogen ; Idec Pharmaceuticals ; Immunex ; Immunology ; ImClone Systems ; Indre et Loire ; Investigational New Drug ; Ireland Cancer Center ; Ivax Corporation ; IVX ; Journal ; Leicester Royal Infirmary ; Leukemia & Lymphoma Society ; Lombardi Cancer Center ; Marketing Authorisation Application ; Medical Devices ; Medicinal Products ; MedImmune ; Memorial Sloan Kettering Cancer Center ; Merck & Co ; Merck KgaA ; Merger & Acquisition Update ; Millennium Pharmaceutical ; MAA ; MD Anderson Cancer Center ; ML ; National Cancer Institute ; Nemod Immuntherapie AG ; Netherlands Cancer Institute ; New Drug Application ; New England Journal ; Novuspharma SpA ; Nurses 's Health ; Ohio State University Medical Center ; Orphan Drug ; Other Cancers News ; Oxford BioMedica ; Pfizer ; PharmaMar ; Point ; Praecis Pharmaceuticals ; Progen Industries ; PGLAF ; PSA ; Regulatory News ; Reuters ; Roche ; Royal Liverpool University Hospital ; Royal Marsden Hospital ; Sanofi Synthelabo Research ; Southern Research Institute ; Stanford Research Institute International ; Stanford University ; State University of New York at Buffalo ; Sundsvall Hospital ; SuperGen ; Sustained Without M & A ; SRI International ; Teva Pharmaceutical ; Texas Health Sciences Center ; Texas MD Anderson Cancer Center ; University of Texas MD Anderson Cancer Center ; Titan Pharmaceuticals ; TransMolecular ; TAP ; University of Chicago ; University of Cologne Aventis Pharma and Mologen ; University of Texas Health Sciences Center ; University of Texas MD Anderson Cancer Center ; University of Wisconsin Medical School ; UK Gene Therapy Advisory Committee ; Washington Hospital Center ; Wisconsin Medical School ; Women 's Health Initiative

...must be provided, which will be caused by a non-specific immune activation similar to **inflammation** reactions. All three signals are

generated by dSLIM.
The study was of a five-armed...

...a tendency to interfere with similar enzymes called sheddases that play a part in secreting **inflammatory** signals. Sheddase inhibition can cause arthritis. BMS275291 was rationally designed using structural biology to aim...cancer target
Scientists from AVI BioPharma have presented research data describing the successful inhibition of **Xiap** , one of a family of genes known to inhibit apoptosis, or programmed cell death, in cancer cells using an **antisense** strategy.
The presentation highlighted results from a series of preclinical studies using AVI BioPharma's Neugene **antisense** technology to block the expression of the gene **Xiap** . In a wide variety of cancers, including prostate cancer, the production of **Xiap** helps tumors grow by preventing apoptosis, which would normally occur in cells damaged by chemotherapy...

...cells that have become resistant to chemotherapy typically exhibit anti-apoptotic behavior. By using Neugene **antisense** drugs to block the **Xiap** gene, the AVI scientists demonstrated that prostate cancer cells that previously became resistant to chemotherapy can be resensitized to chemotherapy drugs. The **Xiap** target was selected over other potential anti-apoptotic targets, such as BCL-2, because of...

...release. "This study builds on our previous experience in several cancer indications, using our Neugene **antisense** drugs to block select genes that are associated with cancer progression. Target selection is a critical component to **antisense** drug development for cancer, and with preclinical data for **Xiap** and androgen receptor targets and clinical data for the c-myc target, we believe we have assembled a robust **antisense** cancer program."
GTx's Acapodene shown to reduces high-grade prostate intraepithelial neoplasia
GTx, Inc...

...sponsored Investigational New Drug application for a clinical trial of Lorus Therapeutics' (LORFF.OB) lead **antisense** drug, GTI-2040 in combination with cytarabine, in patients with refractory or relapsed acute myeloid...three cancer therapies in Biogen's product pipeline. Having traditionally been focused on neurology and **inflammatory** diseases, Biogen looked to find a partner more experienced in oncology. It would seem that ...

27/K/19 (Item 2 from file: 761)

00240994

CANCER: 1.1 THIS MONTH'S HIGHLIGHTS

Main Title: PHARMAWATCH
Pub. Date: July 23, 2003
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 3689 (2 pp.)
Language: English

Features: TABLE
Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Accentia Inc ; American Association for Cancer Research ; American Cancer Society ; American Gastroenterological Association ; American Society of Clinical Oncology ; American Society of Hematology ; American Urological Association ; Amgen ; AnorMed ; Ariad Pharmaceuticals ; AstraZeneca ; Aton Pharma ; ARIA ; AVI BioPharma ; Bayer ; Beatson Cancer Institute ; Beatson Oncology Centre ; Biogen Idec Inc ; Biologics License Application ; Biomira ; Biovest International ; BioTransplant ; Bone Metastases ; Breast Cancer Center of Excellence ; Bristol Myers Squibb ; British Biotech ; BMS/Celltech ; BMY ; Cancer Treatment ; Case Western Reserve University School of Medicine ; Catholic University ; Cell Therapeutics ; Celltech ; Chugai ; Committee for Proprietary Medicinal ; Corixa Corporation ; Department of Defense ; Drug Safety Monitoring Committee ; DNA ; Eli Lilly and Company ; Equal ; European Agency for the Evaluation of Medicinal Products ; European Commission ; European Committee on Proprietary Medicinal ; European Neurological Society ; Genentech ; Genta ; Georgetown University Medical Center ; German Federal Institute for Drugs ; GlaxoSmithKline ; GASTRO ; GTx Inc ; GTAC ; GTI ; Idec Biogen ; Idec Pharmaceuticals ; Immunex ; Immunology ; ImClone Systems ; Indre et Loire ; Investigational New Drug ; Ireland Cancer Center ; Ivax Corporation ; IVX ; Journal ; Leicester Royal Infirmary ; Leukemia & Lymphoma Society ; Lombardi Cancer Center ; Marketing Authorisation Application ; Medical Devices ; Medicinal Products ; MedImmune ; Memorial Sloan Kettering Cancer Center ; Merck & Co ; Merck KgaA ; Merger & Acquisition Update ; Millennium Pharmaceutical ; MAA ; MD Anderson Cancer Center ; ML ; National Cancer Institute ; Nemod Immuntherapie AG ; Netherlands Cancer Institute ; New Drug Application ; New England Journal ; Novuspharma SpA ; Nurses 's Health ; Ohio State University Medical Center ; Orphan Drug ; Other Cancers News ; Oxford BioMedica ; Pfizer ; PharmaMar ; Point ; Praecis Pharmaceuticals ; Progen Industries ; PGLAF ; PSA ; Regulatory News ; Reuters ; Roche ; Royal Liverpool University Hospital ; Royal Marsden Hospital ; Sanofi Synthelabo Research ; Southern Research Institute ; Stanford Research Institute International ; Stanford University ; State University of New York at Buffalo ; Sundsvall Hospital ; SuperGen ; Sustained Without M & A ; SRI International ; Teva Pharmaceutical ; Texas Health Sciences Center ; Texas MD Anderson Cancer Center ; University of Texas MD Anderson Cancer Center ; Titan Pharmaceuticals ; TransMolecular ; TAP ; University of Chicago ; University of Cologne Aventis Pharma and Mologen ; University of Texas Health Sciences Center ; University of Texas MD Anderson Cancer Center ; University of Wisconsin Medical School ; UK Gene Therapy Advisory Committee ; Washington Hospital Center ; Wisconsin Medical School ; Women 's Health Initiative

...must be provided, which will be caused by a non-specific immune activation similar to **inflammation** reactions. All three signals are generated by dSLIM.
The study was of a five-armed...

...a tendency to interfere with similar enzymes called sheddases that play a part in secreting **inflammatory** signals. Sheddase inhibition can cause arthritis. BMS275291 was rationally designed using structural biology to aim...cancer target
Scientists from AVI BioPharma have presented research data describing the successful inhibition of **Xiap** , one of a family of genes known to inhibit apoptosis, or programmed cell death, in cancer cells using an **antisense** strategy.
The presentation highlighted results from a series of preclinical studies using AVI BioPharma's Neugene **antisense** technology to block the expression of the gene **Xiap** . In a wide variety of cancers, including prostate cancer, the production of **Xiap** helps tumors grow by preventing apoptosis, which would normally occur in cells damaged by chemotherapy...

...cells that have become resistant to chemotherapy typically exhibit anti-apoptotic behavior. By using Neugene **antisense** drugs to block the **Xiap** gene, the AVI scientists demonstrated that prostate cancer cells that previously became resistant to chemotherapy can be resensitized to chemotherapy drugs. The **Xiap** target was selected over other potential anti-apoptotic targets, such as BCL-2, because of...

...release. "This study builds on our previous experience in several cancer indications, using our Neugene **antisense** drugs to block select genes that are associated with cancer progression. Target selection is a critical component to **antisense** drug development for cancer, and with preclinical data for **Xiap** and androgen receptor targets and clinical data for the c-myc target, we believe we have assembled a robust **antisense** cancer program."
GTx's Acapodene shown to reduces high-grade prostate intraepithelial neoplasia
GTx, Inc...

...sponsored Investigational New Drug application for a clinical trial of Lorus Therapeutics' (LORFF.OB) lead **antisense** drug, GTI-2040 in combination with cytarabine, in patients with refractory or relapsed acute myeloid...three cancer therapies in Biogen's product pipeline. Having traditionally been focused on neurology and **inflammatory** diseases, Biogen looked to find a partner more experienced in oncology. It would seem that ...

27/K/20 (Item 3 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00203248

BIOTECH: 5.0 NEWS HEADLINES: GENOMICS

Main Title: HEALTHCARE REVIEW
Pub. Date: November 01, 2002
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 2223 (2 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE

Company Names (DIALOG Generated): Applera Corporation ; Applied Biosystems Group ; Asterand ; Biologics License Application ; BioMarin Pharmaceutical ; Bristol Myers Squibb ; Celera Diagnostics ; Celera Genomics Group ; Chapel Hill School ; Charles River Laboratories ; Clinical Cancer Research ; Comprehensive Cancer Center ; Genzyme Biosurgery ; Genzyme Corp ; Hybridon ; Isis Pharmaceuticals ; Jackson Laboratory ; Jefferson Medical College ; Leukaemia Research Fund ; Massachusetts General Hospital ; Merck & Co ; National Institute of Allergy and Infectious Diseases ; National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health; Onyvax ; Pennsylvania School ; Perlegen Sciences ; Pittsburgh Cancer Institute ; Pittsburgh School ; Proteome Systems ; Rockefeller University ; Southern Methodist University ; Stanford University Medical Center ; Target Discovery Program ; Targeted Genetics ; Texas M D Anderson Cancer Center ; Trademark Office ; University of Michigan ; University of North Carolina at Chapel Hill School ; University of Pennsylvania School of Medicine ; University of Pittsburgh Cancer Institute ; University of Pittsburgh School of Medicine ; University of Texas M D Anderson Cancer Center ; UNC ; Wake Forest University School of Medicine ; Wistar Institute

...separate lawsuits, for alleged infringement of its functional genomics US patents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to the **XIAP** gene.
Sangamo granted US zinc finger DNA-binding proteins patent
Sangamo BioSciences has been granted...

...in Neuron, could help scientists devise new strategies to block the pain hypersensitivity associated with **inflammation** .
Wake Forest receives $20 million NIH grant to oversee diabetes genetics study
Wake Forest University...

...illnesses such as cancer and Alzheimer's disease.
Interim results of AVI's phase II **antisense** trial for cardiovascular restenosis confirm safety and efficacy
AVI BioPharma has released positive interim results of a phase II clinical trial measuring the safety and efficacy of its **antisense** compound, Resten-NG, when delivered via catheter during balloon angioplasty procedures.
Xenon Genetics adds two...anorexia nervosa.
Lexicon Genetics discovers new role for protein to develop antibody for treatment of **inflammation**
Lexicon Genetics has discovered a new role in the immune system for a secreted protein that may serve as a target for the development of drugs to treat **inflammation** associated with arthritis and autoimmune disease.
Targeted Genetics cystic fibrosis gene therapy meets primary endpoint...
...key problems in the disease.
Deltagen identifies a novel antibody target for potential treatment of **inflammatory** disorders
Deltagen has discovered a novel drug target, designated DT044I, for the potential treatment of **inflammatory** disorders, including rheumatoid arthritis. This target flows from the company's high-throughput identification screens...

27/K/21 (Item 4 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00203191

CANCER: 7.0 NEWS HEADLINES: COLORECTAL

Main Title: HEALTHCARE REVIEW
Pub. Date: November 01, 2002
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 3846 (3 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Access Pharmaceuticals ; Actinium Pharmaceuticals ; Adherex Technologies ; Advanced Viral Research ; Advectus Life Sciences ; American Association for the Advancement of Science ; Arius Research ; AxCell Biosciences ; AEterna Laboratories ; Biomira ; Bioniche Life Sciences ; BioCryst Pharmaceuticals ; Cancer Research ; Cell Therapeutics ; Chugai Pharmaceutical ; Clinical Cancer Research ; Comprehensive Cancer Center ; Cytogen ; CIMYM ; Dana Farber/Partners ; FDA 's Office of Orphan Products Development ; Genentech ; Genta ; GenVec ; Guilford Pharmaceuticals ; GPC Biotech ; Holden Comprehensive Cancer Center ; Hybridon ; HL ; Idec Pharmaceuticals ; IntraBiotics Pharmaceuticals ; Isis Pharmaceuticals ; Jackson Laboratory ; King Pharmaceuticals ; Leland Stanford Junior University ; Leukaemia Research Fund ; M D Anderson Cancer Center ; Maxim Pharmaceuticals ; Maxygen ; Mayne Group ; Mayo Clinic Cancer Center ; Medical Devices ; Memorial Sloan Kettering Cancer Center ; Merck ; Montefiore Medical Center ; MGI Pharma ; National Cancer Institute ; NeoTherapeutics ; New Drug Application ; Nippon Shinyaku ; North Carolina Brain Tumor Center ; Novartis Ophthalmics ; Orphan Products Development ; Ortho Biotech ; Oxford GlycoSciences ; OSI Pharmaceuticals ; Peregrine Pharmaceuticals ; Pharmaceutical Research and Manufacturers ; Pittsburgh Cancer Institute ; Protein Design Labs ; Rockefeller University ; Royal North Shore Hospital ; Southern Methodist University ; Stanford University ; SLIL Biomedical ; Texas M D Anderson Cancer Center ; National Cancer Institute ; Ohio State University ; University of Iowa ; University of North Carolina Brain Tumor Center ; University of Texas MD Anderson Cancer Center ; Trademark Office ; University of California at San Francisco ; University of North Carolina at Chapel Hill ; University of Pittsburgh Cancer Institute ; University of Texas M D Anderson Cancer Center ; University of Wisconsin ; University of Zurich ; UNC ; Vical ; Vion Pharmaceuticals ; Viventia Biotech ; Washington University School of Medicine

...a terminal brain cancer for which there is no known cure.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to

the **XIAP** gene.
National Institutes of Health funds Seattle Genetics prodrug study
Seattle Genetics has won a...

...and neck radiation therapy used in the treatment of various cancers.

Isis awarded patent for **antisense** compounds
Isis Pharmaceuticals has been issued a US patent covering **antisense** compounds targeted to genes encoding p38 mitogen activated protein kinases or p38 MAP kinases. p38 MAP kinases regulate many biological processes related to **inflammatory** diseases and cancer.
Vical stops Allovectin-7 melanoma program
Vical Incorporated has discontinued its low...

27/K/22 (Item 5 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00203178

REVIEW: 36.0 NEWS HEADLINES: ALLIANCES AND JOINT VENTURES

Main Title: GLOBAL HEALTHCARE
Pub. Date: November 01, 2002
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 1481 (1 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Alza Corporation ; American Heart Association ; Aventis Pasteur ; AAI International ; AM Pharma Holding ; Bayer ; Blue Cross & Blue Shield ; Cambridge Antibody Technology ; Cancer Treatment ; Cel Sci ; Center for Drug Evaluation and Research of the FDA ; Chugai ; Epicyte Pharmaceutical ; Genentech ; Genta ; Hybridon ; Institute 's Molecular Radiation ; Ista Pharmaceuticals ; Kos Pharmaceuticals ; Merck & Co ; National Cancer Institute ; National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health; Nautilus Biotech ; Naval Medical Research Center of the US Navy ; New Drug Application ; Organogenesis ; Perlegen Sciences ; Pharma ; ProMetic Life Sciences ; Radiation Oncology Sciences Program ; Raptiva ; Senju Pharmaceutical Co ; Speedel Group ; Tanabe Holding America ; Tanabe Seiyaku ; University of North Carolina ; US National Cancer Institute ; Wake Forest University School of Medicine ; Xoma

...treatment of HIV-1 infection in combination with other antiretroviral agents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to the **XIAP** gene.
Raptiva achieves primary efficacy endpoint in phase III psoriasis study
Results of a randomized...certain other COX-inhibiting nitric oxide-donators in Japan in the treatment of pain and **inflammation** .

Cambridge Antibody Technology and Chugai enter novel human monoclonal antibodies development partnership
Cambridge Antibody Technology...

27/K/23 (Item 6 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00203164

REVIEW: 25.0 NEWS HEADLINES: COLORECTAL

Main Title: GLOBAL HEALTHCARE
Pub. Date: November 01, 2002
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 1274 (1 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Access Pharmaceuticals ; American Association for the Advancement of Science ; AxCell Biosciences ; Biomira ; Clinical Cancer Research ; Cytogen ; Genta ; GenVec ; Guilford Pharmaceuticals ; Hybridon ; Isis Pharmaceuticals ; Maxim Pharmaceuticals ; Maxygen ; Merck ; National Cancer Institute ; New Drug Application ; Ortho Biotech ; Peregrine Pharmaceuticals ; Pharmaceutical Research and Manufacturers ; Pittsburgh Cancer Institute ; Royal North Shore Hospital ; National Cancer Institute ; University of Pittsburgh Cancer Institute ; Vical ; Vion Pharmaceuticals

...a terminal brain cancer for which there is no known cure.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to the **XIAP** gene.
National Institutes of Health funds Seattle Genetics prodrug study
Seattle Genetics has won a...

...and neck radiation therapy used in the treatment of various cancers.

Isis awarded patent for **antisense** compounds
Isis Pharmaceuticals has been issued a US patent covering **antisense** compounds targeted to genes encoding p38 mitogen activated protein kinases or p38 MAP kinases. p38 MAP kinases regulate many biological processes related to **inflammatory** diseases and cancer.
Vical stops Allovectin-7 melanoma program
Vical Incorporated has discontinued its low...

27/K/24 (Item 7 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.

00203161

REVIEW: 23.0 NEWS HEADLINES: GENOMICS

Main Title: GLOBAL HEALTHCARE
Pub. Date: November 01, 2002
Source: DATAMONITOR
Telephone: +44 20 7675 7000
Word Count: 1079 (1 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Biologics License Application ; BioMarin Pharmaceutical ; Genzyme Biosurgery ; Genzyme Corp ; Hybridon ; Isis Pharmaceuticals ; Jackson Laboratory ; Leukaemia Research Fund ; Massachusetts General Hospital ; Merck & Co ; National Institute of Allergy and Infectious Diseases ; National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health; Pennsylvania School ; Perlegen Sciences ; Southern Methodist University ; Stanford University Medical Center ; University of North Carolina ; University of Pennsylvania School of Medicine ; UNC ; Wake Forest University School of Medicine ; Wistar Institute

...separate lawsuits, for alleged infringement of its functional genomics US patents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to the **XIAP** gene.
Sangamo granted US zinc finger DNA-binding proteins patent
Sangamo BioSciences has been granted...

...in Neuron, could help scientists devise new strategies to block the pain hypersensitivity associated with **inflammation** .
Wake Forest receives $20 million NIH grant to oversee diabetes genetics study
Wake Forest University...

...illnesses such as cancer and Alzheimer's disease.
Interim results of AVI's phase II **antisense** trial for cardiovascular restenosis confirm safety and efficacy
AVI BioPharma has released positive interim results of a phase II clinical trial measuring the safety and efficacy of its **antisense** compound, Resten-NG, when delivered via catheter during balloon angioplasty procedures.
Xenon Genetics adds two...

27/K/25 (Item 1 from file: 993)
DIALOG(R)File 993:NewsRoom 2002

0513541041 15Y3182J
OTHER NEWS TO NOTE.
BioWorld Today, v13, n179, pNA
Wednesday, September 18, 2002
JOURNAL CODE: AAFH LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newsletter
WORD COUNT: 2,759

...validate a number of drug targets associated with cancer. Atugen will develop GeneBlocs, specially designed **antisense** oligonucleotides, which inhibit expression of specific drug target candidates selected by Schering. Though specific financial...

...of Montreal, formed an agreement in which Hybridon will collaborate with Aegera to develop an **antisense** drug candidate targeted to down-regulate Aegera's target, **XIAP** , which has been implicated in the resistance of cancer cells to chemotherapy. The drug candidate...

...Hybridon licensed to Aegera, on a nonexclusive basis, rights to a portfolio of second-generation **antisense** chemistries and oral **antisense** delivery intellectual property owned or licensed by Hybridon. Aegera will pay Hybridon certain collaboration, up...

...a license to certain Isis patents for target validation and functional genomics using first-generation **antisense** oligonucleotides in exchange for undisclosed payments from Sequitur. Subject to a limited right to conclude existing contracts, Sequitur agreed to not practice in the field of second- or next- generation **antisense** oligonucleotides, also known as chimeric **antisense** oligonucleotides.

Keryx Biopharmaceuticals Inc., of Cambridge, Mass., following successful pre-Phase III meetings with the...

...an orally active small- molecule agent that targets a cell-surface protein involved in the **inflammatory** response. The dose-escalation trial will be conducted in up to 30 healthy adult volunteers...

...that Vasogen's immune modulation therapy can significantly reduce cell death induced by lipopolysaccharide, an **inflammatory** stimulus. The attenuation of the **inflammatory** response was associated with an increase in the anti- **inflammatory** cytokine interleukin-10 and a concomitant decrease in the pro- **inflammatory** cytokine interleukin- 1B. The therapy also led to a reduction in the expression of certain enzymes involved in the intracellular response to **inflammation** , including the stress-activated protein kinase c-Jun NH(2)-terminal kinase.

27/K/26 (Item 2 from file: 993)

DIALOG(R)File 993:NewsRoom 2002

0505054968 15XL1PPR

Death receptor-mediated apoptosis and the liver

Yoon, Jung-Hwan

Journal of Herpetology, v37, n3, p400
Sunday, September 1, 2002
JOURNAL CODE: AMRR LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Scholarly Journal ISSN: 0022-1511
WORD COUNT: 7,958

...produced by macrophages including Kupffer cells, monocytes, and T cells in response to infection and **inflammatory** conditions, but also by other cell types, such as B cells, fibroblasts, and hepatocytes. Unlike...

...proteins that regulate the cytochrome c/Apaf- 1 caspase activating pathway [23]. Three human IAPs, **XIAP** , c-IAP-1 and c-IAP-2, have been shown to bind procaspase 9 and...

...hepatitis [57]. Fas expression can be induced either by virus-- specific protein expression or by **inflammatory** cytokines such as interleukin-1. Activated CTLs express Fast and induce hepatocyte apoptosis via Fas...
...to eliminate hepatocytes bearing CCC DNA. Since limited apoptosis can delete cells without inducing untoward **inflammatory** reactions, the differential sensitivity of HBV-infected hepatocytes to TRAIL-induced apoptosis could potentially be...

...DRs use caspase 8/10 and Bid to induce apoptosis, targeted caspase inhibition and Bid **antisense** oligonucleotides could be therapeutically useful in cholestatic liver diseases. For example, Bid **antisense** oligonucleotides have already been shown to be therapeutically useful in a rodent model of extrahepatic...strategy to inhibit liver fibrogenesis. Alternatively, apoptosis in the liver by DRs may be pro- **inflammatory** . For example, administration of Fas agonists in the rodent results in liver chemokine expression, which...

...Lugering N, Held J, Domschke W, et al. Caspase activation correlates with the degree of **inflammatory** liver injury in chronic hepatitis C virus infection. Hepatology 2001;34:758-767.

[57] Mochizuki...

...677.
[71] Higuchi H, Miyoshi H, Bronk SF, Zhang H, Dean N, Gores GJ. Bid **antisense** attenuates bile acid-induced apoptosis and cholestatic liver injury. I Pharmacol Exp Ther 2001;299...

...J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary **inflammation** in vivo. Am J Respir Cell Mol Biol 1995;12:232-237.

[77] Fadok VA...

...Campe CB, Schrum LW, Rippe RA, et al. Anti-Fas induces hepatic chemokines and promotes **inflammation** by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001;276...
? T S28/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

28/K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11277558 PMID: 11356694
X-linked inhibitor of apoptosis protein activates the phosphatidylinositol 3-kinase/Akt pathway in rat granulosa cells during follicular development.
Asselin E; Wang Y; Tsang B K
Reproductive Biology Unit and Division of Reproductive Medicine, Department of Obstetrics and Gynecology and Cellular and Molecular Medicine, University of Ottawa, Canada.
Endocrinology (United States) Jun 2001, 142 (6) p2451-7, ISSN 0013-7227 Journal Code: 0375040

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

X-linked inhibitor of apoptosis protein (**XIAP**) in granulosa cells is regulated by gonadotropins during follicular development, although the current understanding of the mechanisms by which **XIAP** suppressed granulosa cell apoptosis is incomplete. In the present study, we investigated the possible involvement...
... development and atresia in immature rats, we have demonstrated that gonadotropin treatment increased granulosa cell **XIAP** and phospho-Akt protein contents and suppressed apoptosis. In addition, gonadotropin withdrawal [equine CG (eCG...

... apoptosis and significantly decreased ovarian weight. The increased apoptosis was accompanied by marked decreases in **XIAP** expression and phosphorylation of Akt protein. Infection of granulosa cells from eCG-primed rats with adenoviral sense **XIAP** [lacZ as a control; multiplicity of infection, 1-5] resulted in **XIAP** overexpression and increased phospho-Akt content, whereas **XIAP** **antisense** expression (multiplicity of infection, 10-40) decreased granulosa cell phospho-Akt level and induced apoptosis...

... the first time the importance and regulation of the PI 3-K survival pathway by **XIAP** in the control granulosa cell apoptosis.
...; Cultured; Chorionic Gonadotropin--administration and dosage--AD; Chorionic Gonadotropin--immunology--IM; Chorionic Gonadotropin --pharmacology--PD; **Follicular Atresia** ; In Situ Nick-End Labeling; Oligodeoxyribonucleotides, **Antisense** --genetics--GE; Ovarian Follicle --metabolism--ME; Phosphorylation; Proteins--genetics--GE; Rats; Rats, Sprague-Dawley; Transfection
Chemical Name: Antibodies; Chorionic Gonadotropin; IAP-like protein, vertebrate; Oligodeoxyribonucleotides, **Antisense** ; Proteins; Proto-Oncogene Proteins; proto-oncogene protein akt; 1-Phosphatidylinositol 3-Kinase

28/K/2 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit

02728648 21255627 PMID: 11356694
X-linked inhibitor of apoptosis protein activates the phosphatidylinositol 3-kinase/Akt pathway in rat granulosa cells during follicular development.
Asselin E; Wang Y; Tsang B K
Reproductive Biology Unit and Division of Reproductive Medicine, Department of Obstetrics and Gynecology and Cellular and Molecular Medicine, University of Ottawa, Canada.
Endocrinology (United States) Jun 2001, 142 (6) p2451-7, ISSN 0013-7227 Journal Code: 0375040
Document Type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

X-linked inhibitor of apoptosis protein (**XIAP**) in granulosa cells is

regulated by gonadotropins during follicular development, although the current understanding of the mechanisms by which **XIAP** suppressed granulosa cell apoptosis is incomplete. In the present study, we investigated the possible involvement...
... development and atresia in immature rats, we have demonstrated that gonadotropin treatment increased granulosa cell **XIAP** and phospho-Akt protein contents and suppressed apoptosis. In addition, gonadotropin withdrawal [equine CG (eCG...

... apoptosis and significantly decreased ovarian weight. The increased apoptosis was accompanied by marked decreases in **XIAP** expression and phosphorylation of Akt protein. Infection of granulosa cells from eCG-primed rats with adenoviral sense **XIAP** [lacZ as a control; multiplicity of infection, 1-5] resulted in **XIAP** overexpression and increased phospho-Akt content, whereas **XIAP** **antisense** expression (multiplicity of infection, 10-40) decreased granulosa cell phospho-Akt level and induced apoptosis...

... the first time the importance and regulation of the PI 3-K survival pathway by **XIAP** in the control granulosa cell apoptosis.
Minor Descriptors: Antibodies--pharmacology--PD; Apoptosis; Cells, Cultured; **Follicular Atresia** ; Gonadotropins, Chorionic--administration and dosage--AD; Gonadotropins, Chorionic--immunology--IM; Gonadotropins, Chorionic--pharmacology--PD; In Situ Nick-End Labeling; Oligodeoxyribonucle otides, **Antisense** --genetics--GE; Ovarian Follicle--metabolism--ME; Phosphorylation; Proteins--genetics--GE; Rats; Rats, Sprague-Dawley; Transfection
Chemical Name: Antibodies; Gonadotropins, Chorionic; IAP-like protein, vertebrate; Oligodeoxyribonucleotides, **Antisense** ; Proteins; Proto-Oncogene Proteins; proto-oncogene protein akt; 1-Phosphatidylinositol 3-Kinase